José Rafael Romero, M.D.

Name:		José Rafael Romero
Address:	Home:	---------------------- ---------------------
	Work:	Division of Pediatric Infectious Diseases Arkansas Children’s Hospital 800 Marshall St., Slot 512-11  Little Rock, AR 72202-3591
Telephone:		Office:(501) 364-1416 Fax:(501) 364-3551 Home:--------------
E-mail:		RomeroJose@uams.edu
Date of Birth:		------------
Place of Birth:		-------------------
Citizenship:		--------------------------------------
Marital Status:		------

Academic Appointments

Primary Academic Appointments
7.1.08 – Present	Professor of Pediatrics (Tenured) Horace C. Cabe Professor of Pediatrics Division of Pediatrics, Department of Pediatric University of Arkansas for Medical Sciences Little Rock, AR
7.1.04 - 6.30.08	Professor of Pediatrics (Tenured) Section of Pediatric Infectious Diseases, Department of Pediatrics University of Nebraska College of Medicine Omaha, NE
7.1.04 - 6.30.08	Professor of Pathology and Microbiology Department of Pathology and Microbiology University of Nebraska College of Medicine Omaha, NE
7.1.01 - 6.30.08	Tenure conferred  Associate Professor of Pediatrics  Section of Pediatric Infectious Diseases, Department of Pediatrics University of Nebraska College of Medicine Omaha, NE
7.1.98 - 6.30.04	Associate Professor of Pathology and Microbiology Department Pathology and Microbiology University of Nebraska College of Medicine Omaha, NE
7.1.98 - 6.30.04	Associate Professor of Pediatrics Section of Pediatric Infectious Diseases, Department of Pediatrics University of Nebraska College of Medicine Omaha, NE
7.1.93 - 6.30.98	Assistant Professor of Pediatrics Section of Pediatric Infectious Diseases, Department of Pediatrics  University of Nebraska College of Medicine Omaha, NE
7.1.93 - 6.30.98	Assistant Professor of Pathology and Microbiology Department Pathology and Microbiology University of Nebraska College of Medicine Omaha, NE
7.1.92 - 6.30.93	Assistant Professor of Pediatrics Section of Pediatric Infectious Diseases, Department of Pediatrics  School of Medicine, University of Colorado Denver, CO
7.1.91 - 6.30.92	Instructor of Pediatrics Section of Pediatric Infectious Diseases, Department of Pediatrics  School of Medicine, University of Colorado Denver, CO
4.1.87 - 5.31.89	Instructor of Pediatrics Department of Pediatrics, School of Medicine,  State University of New York at Stony Brook Stony Brook, NY
2.1.79 - 1.31.80	Clinical Instructor of Gastroenterology (Social Service) Department of Medicine, Division of Gastroenterology School of Medicine, Universidad Autónoma de Guadalajara Guadalajara, Jalisco, MEXICO

Adjunct Academic Appointments
7.1.08 - Present	Professor of Pediatrics Department of Pediatrics University of Nebraska College of Medicine Omaha, NE
1.25.05 - 6.30.08	Adjunct Professor of Pediatrics Department of Pediatrics Creighton University School of Medicine Omaha, NE
1.25.05 - 6.30.08	Adjunct Professor of Medical Microbiology and Immunology Creighton University School of Medicine Omaha, NE
7.1.98 - 1.24.05	Adjunct Associate Professor of Pediatrics Department of Pediatrics Creighton University School of Medicine Omaha, NE
7.1.98 - 1.24.05	Adjunct Associate Professor of Medical Microbiology and Immunology Creighton University School of Medicine Omaha, NE
7.1.93 - 6.30.98	Adjunct Assistant Professor of Pediatrics Department of Pediatrics  Creighton University School of Medicine Omaha, NE
7.1.93 - 6.30.98	Adjunct Assistant Professor of Medical Microbiology and Immunology Creighton University School of Medicine Omaha, NE

Administrative Appointments
Active Appointments
9.7.05 - 6.30.08	Director  Clinical Trials Research Arkansas Children’s Hospital Research Institute Little Rock, AR
Completed Appointments
9.7.05 - 6.30.08	Director Section of Pediatric Infectious Diseases University of Nebraska Medical Center Omaha, NE
5.1.01 – 6.1.08	Medical Advisor Douglas County Health Department Omaha, NE
3.1.99 – 6.30.08	Director Pediatric Infectious Diseases Fellowship Program Combined Division of Pediatric Infectious Diseases Departments of Pediatrics University of Nebraska Medical Center/Creighton University Omaha, NE
10.1.02 – 7.31.07	Director for Latino Health-Related Research Affairs Minority Health Education and Research Office University of Nebraska Medical Center Omaha, NE
7.1.06 - 2.28.07	Director Minority Health Education and Research Office University of Nebraska Medical Center Omaha, NE
7.1.05 - 6.30.06	Interim Director Minority Health Education and Research Office University of Nebraska Medical Center Omaha, NE
1.1.03 - 9.7.05	Director Combined Section of Pediatric Infectious Diseases Departments of Pediatrics University of Nebraska Medical Center/Creighton University Omaha, NE
7.10.01 - 12.31.03	Chief Recruitment Officer for Latino Students University of Nebraska College of Medicine Omaha, NE
4.20.01 - 2.28.03	Interim Director Combined Division of Pediatric Infectious Diseases Departments of Pediatrics Creighton University/University of Nebraska Medical Center Omaha, NE
7.1.98 - 12.31.00	Co-Director, Medical Education Children’s Hospital Omaha, NE
7.96 - 2.28.99	Associate Director, Pediatric Infectious Diseases Fellowship Program Combined Division of Pediatric Infectious Disease, Departments of Pediatrics University of Nebraska Medical Center/Creighton University Omaha, NE

State, National and International Committee Appointments
Active Appointments
2009 – 2010	Member-USMLE Step 1 Microbiology Test Material Development Committee National Board of Medical Examiners Philadelphia, PA
2007 - Present	Member- Vaccines and Related Biological Products Advisory Committee  (VRBPAC) Food and Drug Administration (FDA) Center for Biologics Evaluation and Research
3.7.05 - 6.30.08	Member- Governor’s Pandemic Influenza Committee Office of the Governor Department of Health and Human Services System State of Nebraska Lincoln, NE
Completed Appointments
3.04 - 5.01.08	Member- Tuberculosis Advisory Committee Department of Health and Human Services System State of Nebraska Lincoln, NE
2003 - 2005	Member- American Board of Pediatrics Chapel Hill, NC
2002 - 2005	Policy Advisor-Administration of Mexican President Vicente Fox Subcommittee on Health-Related Affairs Advisory Council of the Institute for Mexicans Abroad Mexican Ministry of Foreign Affairs
2002 - 2006	Member, National Institutes of Heath, Collaborative Antiviral Study Group  Natural History of Myocarditis in Children Study Protocol Design Team
2001 - 2005	Member- Infectious Diseases Credentials Committee American Board of Pediatrics Chapel Hill, NC
2000 - 2005	Member- Pediatric Infectious Diseases Sub-Board  American Board of Pediatrics Chapel Hill, NC
8.02 - 12.04	Member- Ad Hoc Committee to Prioritize for Limited Smallpox Vaccination Department of Health and Human Services System State of Nebraska Lincoln, NE
2000 - 2002	Associate Member- American Board of Pediatrics Chapel Hill, NC

Clinical Appointments
1998 – 5.31.08	Volunteer Staff OneWorld Community Health Center (Formerly Indian-Chicano Hlth Center) Omaha, NE
1.90 - 6.30.92	Attending Physician Kids Care Clinic Denver General Hospital Denver, CO

Education
Medical School ---------------	Universidad Autónomade Guadalajara Guadalajara, Jalisco MEXICO
High School ---------	Bellarmine College Preparatory San Jose, California

Postdoctoral Training
7.21.04	Strengths 101 The Gallop University Workshop Omaha, NE
1.22-23.03	Smallpox Vaccine Adverse Event Workshop State Health Department Training Centers for Disease Control and Prevention Atlanta, GA
7.1.91 - 6.30.93	Fellow, Robert Wood Johnson Foundation  Minority Medical Faculty Development Program Department of Pediatrics, Section of Pediatric Infectious Diseases School of Medicine, University of Colorado Denver, Colorado
6.1.89 - 6.30.92	Clinical Fellow, Pediatric Infectious Diseases, PGY-9, PGY-10 Department of Pediatrics, Section of Pediatric Infectious Diseases School of Medicine, University of Colorado Denver, CO
6.1.89 - 6.30.90	Research Fellow, Neurovirology Training Program, PGY-8 Department of Pediatrics, Section of Pediatric Infectious Diseases School of Medicine, University of Colorado Denver, CO
7.1.87 - 6.30.89	Fellow, Robert Wood Johnson Foundation-  Minority Medical Faculty Development Program Department of Pediatrics, School of Medicine, State University of New York at Stony Brook Stony Brook, NY
7.1.84-3.31.87	Research Fellow, PGY-5, PGY-6, PGY-7 Molecular Microbiology Departments of Microbiology and Pediatrics School of Medicine, State University of New York at Stony Brook Stony Brook, NY
7.1.83 - 6.30.84	Chief Resident, PGY-4 Department of Pediatrics, University Hospital, School of Medicine, State University of New York at Stony Brook Stony Brook, NY
7.1.81 - 3.31.83	Pediatric Resident, PGY-2, PGY-3 Department of Pediatrics, University Hospital,  School of Medicine, State University of New York at Stony Brook Stony Brook, NY
7.1.80 - 6.30.81	Pediatric Intern, PGY-1 Department of Pediatrics, University Hospital,  School of Medicine, State University of New York at Stony Brook Stony Brook, NY
3.24.80 - 6.30.80	Postdoctoral Research Associate Surgery/Transplantation State University of New York at Stony Brook Stony Brook, NY
1.1.78-12.31.78	Rotating Internship Centro Médico del Noroeste Hermosillo, Sonora, MEXICO

Degrees, Certificates and Licensures
5.21.2000	Sub-Specialty Board Recertification - Pediatric Infectious Diseases American Board of Pediatrics
11.15.1994	Sub-Specialty Board Certified- Pediatric Infectious Diseases American Board of Pediatrics
11.1994	Elected Fellow of the Graduate College of the University of Nebraska, University of Nebraska Medical Center, Omaha, NE
7.28.1993	Nebraska State License-Issued (-----)
10.12.1989	Colorado State License-Issued (-----)
4.30.1988	Board Certified- American Board of Pediatrics (-----)
9.12.1986	American Board of Pediatrics Exam (Written)-Passed
3.25.1985	New York State License-Issued (------)
12.6.1984	FLEX Examination-Passed (---------------)
11.2.1983	ECFMG Certificate-Issued (----------)
6.25.1981	Mexican Medical License-Issued (------)
1.21.1979	Mexican Licensure Examination-Passed
12.10.1977	Médico Cirujano Universidad Autónoma de Guadalajara Guadalajara, Jalisco, MEXICO
7.27.1977	ECFMG Examination-Passed

Awards and Honors
2008	Horace C. Cabe Professor of Pediatrics Department of Pediatrics, School of Medicine University of Arkansas for Medical Sciences Little Rock, AR
2008	Outstanding Academic Faculty Member Teaching Award Pediatric Residency Program Creighton/Nebraska Universities Health Foundation Omaha, NE
2008	Nominated for Hobart E. Wiltse, MD, PhD Excellence in Medical Education Award Nebraska-Creighton Universities Joint Pediatric Residency Program Omaha, NE
2007 - 2008	Named to Best Doctors in America
2005 - 2006	Named to Best Doctors in America
2006	Included in Who’s Who in American Education
2005	Nominated for Robert D. Sparks Award in Public Health and Preventative Medicine University of Nebraska Medical Center and  University of Nebraska at Omaha Omaha, NE
2005	Nominated for Golden Apple Teaching Award School of Medicine- Creighton University Omaha, NE
2005	Included in Who’s Who in Medical Sciences Education
2004	Distinguished Service Award  The Nebraska Infection Control Network State of Nebraska
2003	Elected Faculty Member  Alpha Omega Alpha National Honor Society Alpha of Nebraska Chapter
2003 - 2004	Named to Best Doctors in America  20032003 Latinos On The Move Community Award Human Relations Department City of Omaha, NE
2003	Nominated for Hirschmann Prize for Teaching Excellence University of Nebraska Medical Center Omaha, NE
2002	2002 Milagro Award Recipient Indian-Chicano Health Center Omaha, NE
2002	Dr. Stephen A. Chartrand Memorial Award for Outstanding Faculty Creighton-Nebraska Universities Joint Pediatric Residency Program Omaha, NE
2001-2002	Named to Best Doctors in America
1999 - Present	Included in Who’s Who in Medicine and Healthcare
1999	Nominated for Outstanding Investigator University of Nebraska Medical Center Omaha, NE
1996	Nominated for Golden Apple Teaching Award University of Nebraska Medical Center,  Omaha, NE
11.95	Charles A. Monasee Faculty Development Award Creighton University Omaha, NE
4.95	Outstanding Faculty Teaching Award Departments of Pediatrics Joint Residency Program Creighton/Nebraska Universities Health Foundation Omaha, NE
6.11.93	Gary Way Award For Outstanding Teaching 1992-1993 Department of Pediatrics, University of Colorado Denver, Colorado
7.1.91 - 6.30.93	Fellow, Minority Medical Faculty Development Program Robert Wood Johnson Foundation Princeton, NJ
7.1.87 - 6.30.89	Fellow, Minority Medical Faculty Development Program Robert Wood Johnson Foundation Princeton, NJ
2.2.1980	Outstanding Clinical Instructor, Department of Gastroenterology Universidad Autónoma de Guadalajara Guadalajara, Jalisco, MEXICO
12.31.1978	Outstanding Intern Centro Médico del Noroeste Hermosillo, Sonora, MEXICO
----------	Graduated Top 1% of Medical School Class Universidad Autónoma de Guadalajara Guadalajara, Jalisco, MEXICO

Patents
1999	Molecular determinants of tropism and virulence in enteroviruses. Provisional Patent Application No. 60/143,104.

Memberships in Professional Socities

Alpha-Omega-Alpha National Honor Society (2003)- Life Member

American Academy of Pediatrics (-------)

American Association for the Advancement of Science (1993) (---------)

American Board of Pediatrics (2000)- Member

American Society for Microbiology (--------)

American Society for Virology- Life Member

Association for Academic Minority Physicians- Associate Member

Infectious Diseases Society of America (-------)

Nebraska Chapter, American Academy of Pediatrics

National Hispanic Medical Association (2004)

New York Academy of Sciences

Pan American Society for Clinical Virology- Life Member

Pediatric Infectious Diseases Society (-----)

Section on Infectious Diseases, American Academy of Pediatrics (2007)- Member

Society for Advancement of Chicanos and Native Americans in Science- Life Member (-----)

Society for Pediatric Research

Study Sections, Grant Reviewer, Site Reviewer
Active Appointments
2004 - Present	Member- Infectious Diseases Review Panel  Congressionally Directed Peer Reviewed Medical Research Program (PRMRP) United States Army Medical Research and Material Command American Institute of Biological Sciences
2004 - Present	Reviewer- Research Proposals Viral Diseases Panel Military Infectious Diseases Research Project (MIDRP) United States Army Medical Research and Material Command American Institute for Biological Sciences

Completed Appointments
2006 - 2007	Co-Chairman- MedImmune Pediatric Fellowship Grant Program MedImmune, Inc. Gaithersburg, MD
2004 - 2007	Reviewer- MedImmune Pediatric Fellowship Grant Program MedImmune, Inc. Gaithersburg, MD
9.21-22.2006	Member- USMLE Step 1 Standard Setting Panel National Board of Medical Examiners Philadelphia, PA
2005	Reviewer- Task Research Plans Integrating Integrated Product Team (IIPT) Military Infectious Diseases Research Project (MIDRP) American Institute of Biological Sciences
2003	Reviewer- Research Proposals Institute Pasteur Paris, France
2001 - 2002	Reviewer- Abstracts- Infectious Diseases Pediatric Academic Societies
2001	Site Reviewer- Department of Pediatrics Training Program External Review Wayne State University/Children’s Hospital of Michigan Detroit, Michigan
2001	Reviewer (ad hoc)- Research Proposals U.S. Department of Agriculture
2000	Reviewer (ad hoc)- Research Proposals American Lung Association
1999	Reviewer- Research Proposals South Dakota Health Research Foundation
1993	Study Section Member- Research leading to improved measles vaccine National Institute of Allergy and Infectious Diseases RFA: AI-93-06

Meetings, Organized, Convenor, Moderator
12.14-15.07	Chairman- Respiratory Syncytial Virus Managed Care Advisory Board MedImmune, Inc Washington, DC
10.10-11.2007	Co-Chairman- Perspectives on Assessing the Value of RSV Prophylaxis MedImmune Advisory Board Chicago, IL
2.03.2006	Moderator- Health Disparities: Cancer and Heart Disease Fifth Social Equity Leadership Conference National Academy of Public Administration Omaha, NE
10.10-11.2006	Co-Chairman- Pediatric Infectious Diseases Advisory Board MedImmune Advisory Board Toranto, Canda
10.2005 - 3.2007	Co-Chairman- Pediatric Infectious Diseases Advisory Board MedImmune, Inc. Gaithersburg, MD
9.25.2003	Moderator- Education and Healthcare Challenges Facing Latino Immigrants  Lunch and Learn Series  The Nebraska Medical Center Omaha, NE
11.12.02	Moderator- Enhancing Latino Participation in Clinical Trials Panel Discussion Third Annual Heartland Latino Leadership Conference Omaha, NE
1994 - 2001	Co-organizer- Nebraska Intercampus Virology Conferences
9.4.2002	Moderator- Reaching Out to Our Minority Populations Nebraska Rural Health Association Annual Conference Kearney, NE
10.8.2000	Convener- Viral Pathogenesis/Host Resistance Session Tenth Annual Nebraska Intercampus Virology Meeting Mahoney State Park, NE
7.12.1999	Convener, Picornavirus Workshop. 18th Annual Meeting of the American Society for Virology,  University of Massachusetts, Amherst, MA

AD HOC JOURNAL REVIEWER:

Active

Ambulatory Pediatrics (2004-Present)

Archives of Pediatrics & Adolescent Medicine (2001-Present)

Clinical Infectious Diseases (1997-Present)

Emerging Infectious Diseases (2004-Present)

Journal of Antimicrobial Agents and Chemotherapy (2003-Present)

Journal of Clinical Investigation (2004-Present)

Journal of Clinical Virology (2005-Present)

Journal of Infectious Diseases (2000-Present)

Journal of Pediatrics (2004-Present)

Journal of Virology (1997-Present)

Pediatric Infectious Disease Journal (1997-Present)

Pediatrics (1999-Present)

Pediatric Research (2005-Present)

Past

Canadian Journal of Microbiology (2005)

American College of Physicians Medicine (2005)

Doody Publishing Book Review Service (1999-2002)

Annals of Epidemiology (2001)

Virus Research (1998)

Journal of Virological Methods (1998)

Biotechniques (1997)

Journal of Clinical Microbiology (1993-1996)

Molecular and Cellular Probes (1996)

Journal of Medical Virology (1996)

Consultant
Active
7.06 - Present	Consultant Mead Johnson & Company Evansville, Indiana
2004 - Present	Medical Consultant- Tuberculosis Control Program Department of Health and Human Services System State of Nebraska
2001 - Present	Medical Consultant- Nebraska Medicaid  Department of Health and Human Services System, State of Nebraska Lincoln, NE
Past
2003 - 2007	Pediatric Infectious Disease Advisory Board MedImmune, Inc. Gaithersburg, MD
10.06 - 2007	Consultant Elan Pharmaceuticals, Inc. San Diego, CA
2006	Clinical Advisory Board Member Cepheid Sunnyvale, CA
2005	Advisory Board Member- ------------------------------------------ GlaxoSmith Kline Research Triangle Park, NC
4.05 - 2007	El SIDA Program Advisory Council Nebraska AIDS Project Omaha, NE
2002 - 2004	Pediatric National Advisory Board GlaxoSmith Kline Research Triangle Park, NC
2002 - 2005	The Synagis® Outcomes Registry Advisory Board MedImmune, Incorporated Gaithersburg, MD
1995 - 2003	ViroPharma, Incorporated Exton, PA

University Service
Active Appointments
2000 - Present	Member- Graduate Medical Education Committee College of Medicine University of Nebraska Medical Center Omaha, NE
Completed Appointments
8.07 - 6.08	Member- Diversity Advisory Steering Committee University of Nebraska Medical Center/University of Nebraska at Omaha Omaha, NE
8.05 - 5.08	Vice Chairperson- Institutional Biosafety Committee University of Nebraska Medical Center/University of Nebraska at Omaha Omaha, NE
11.04 - 5.08	Member- Institutional Biosafety Committee (UNMC/UNO Biosafety Cmte) University of Nebraska Medical Center/University of Nebraska at Omaha Omaha, NE
7.04 - 2006	Member- Nebraska Biocontainment Unit Advisory Committee University of Nebraska Medical Center Omaha, NE
2002 - 2007	Member- Continuing Medical Education Committee University of Nebraska College of Medicine Omaha, NE
2002 - 3.08	Member- Institutional Review Board University of Nebraska Medical Center Nebraska Health System (University Hospital & Clarkson Hospital) Omaha, NE
2001 – 6.08	Member- Promotion and Tenure Review Committee Department of Pediatrics University of Nebraska Medical Center Omaha, NE
1998 – 3.08	Member- Pharmacy and Therapeutics Committee Nebraska Health System(University Hospital & Clarkson Hospital) Omaha, NE
2002 - 2007	Member- Minority Health Research Group University of Nebraska Medical Center Omaha, NE
4.05 - 12.06	Member- Task Force on Research Chancellor’s NCACS Accreditation Steering Committee  University of Nebraska Medical Center Omaha, NE
3.05 - 6.05	Chairman- Pain Management Fellowship Internal Review Graduate Medical Education Committee College of Medicine University of Nebraska Medical Center Omaha, NE
2004 - 2006	Member- Science and Technology Advisory Committee University of Nebraska Medical Center Omaha, NE
8.03 - 11.03	Chairman- Hematololgy/Oncology Fellowship Internal Review Graduate Medical Education Committee College of Medicine University of Nebraska Medical Center Omaha, NE
3.01 - 6.03	Member- Executive Cultural Competence Steering Committee College of Medicine University of Nebraska Medical Center Omaha, NE
4.96 - 11.04	Member- Biosafety Committees University of Nebraska Medical Center and  University of Nebraska, Omaha Omaha, NE
9.02 - 12.02	Chairman- Minority Access to Research Subcommittee Institutional Review Board University of Nebraska Medical Center Omaha, NE
12.01 - 6.04	Member- Bioterrorism Steering Committee Nebraska Health System (University Hospital and Clarkson Hospital) Omaha, NE
4.01 - 6.02	Member- Pediatric Department Chairperson Search Committee Creighton University Omaha, NE
10.01 - 3.02	Chairman- Pulmonary Fellowship Internal Review Graduate Medical Education Committee College of Medicine University of Nebraska Medical Center Omaha, NE
5.98 - 8.98	Member- Search Committee for Director of the Office of Student Equity and Multicultural Affairs  University of Nebraska Medical Center Omaha, NE
2.95 - 2.98	Member- Pharmacy and Therapeutics Committee University of Nebraska Medical Center Omaha, NE
1993 - 1995	Member- Task Force on Culturally Competent Care University of Nebraska Medical Center Omaha, NE
1992 - 1993	Member- Minority Resident Recruitment Committee School of Medicine, University of Colorado Denver, CO
1988 - 1989	Member- Infection Control Committee University Hospital at Stony Brook, State University at Stony Brook Stony Brook, NY
1987 - 1989	Member- Admissions Committee, School of Medicine  School of Medicine, Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
1986 - 1989	Member- University Health Service Advisory Board State University of New York at Stony Brook Stony Brook, NY
1983 - 1989	Member- House Staff Committee University Hospital at Stony Brook, State University of New York at Stony Brook Stony Brook, NY

Departmental and Divisional Service
Active Appointments
Completed Appointments
1.06 - 2.08	Member- Medical Executive Committee Children’s Hospital Omaha, NE
2.97 - 2.08	Chairman- Pharmacy and Therapeutics Committee Children's Hospital Omaha, NE
1.95 - 2.08	Member- Pharmacy and Therapeutics Committee Children's Hospital Omaha, NE
8.98 - 1.01	Member- Tri-Institutional Education Committee Children’s Hospital, Creighton University &  University of Nebraska Medical Center Omaha, NE
12.94 - 2.96	Member- Febrile Infant Task Force Committee Children's Hospital Omaha, NE
1992 - 1993	Coordinator of Medical Education Section of Pediatric Infectious Diseases University of Colorado Denver, CO
1986 - 1989	Member- Residency Review Committee Department of Pediatrics  School of Medicine, Health Sciences Center,  State University of New York at Stony Brook Stony Brook, NY

Community Service
Active
5.99 - Present	Executive Director, President and Founder Foundation for Molecular Virology Research Omaha, NE
Past
6.97 – 5.08	Co-Founder and Health Care Provider- Tuberculosis Clinic Indian-Chicano Clinic (The OneWorld Community Health Center) Omaha, NE
2006- 4.08	Member- Planning, Allocation and Community Development Cabinet United Way of the Midlands Omaha, NE
3.04 - 4.08	Member- Board of Directors United Way of the Midlands Omaha, NE
3.03 - 4.08	Member- Board of Directors The OneWorld Community Health Center Omaha, NE
11.05 – 2.08	Member- Board of Directors Catholic Charities Omaha, NE
3.05 - 3.06	Ex-officio President-Board of Directors Chicano Awareness Center Omaha, NE
10.27.05	Member- Rx for Kids: Nebraska Connects Panel Nebraska Educational Television Lincoln, NE
3.01 - 2.05	President- Board of Directors Chicano Awareness Center Omaha, NE
3.00 - 2.01	Vice-President- Board of Directors Chicano Awareness Center Omaha, NE
2.99 - 2.05	Member-Board of Directors Chicano Awareness Center Omaha, NE
12.01 - 4.04	“Health Watch” Physician  KETV Channel 7 Omaha, NE
4.02 - 9.02	Member- Search Committee for Medical Director  Douglas County Health Department Omaha, NE
11.02.01	Master of Ceremonies Heartland Latino Leadership Conference Omaha, NE
2.97 - 12.00	Member- United Latino Endowment Scholarship Committee Omaha, NE
3.00-3.01	Vice President, Board of Directors Chicano Awareness Center Omaha, NE
1997 - 2000	Speaker- “Careers in Medicine” - Career Speaking Program Omaha Job Clearinghouse, School-To-Career Program South High School, Omaha, NE (Program terminated)
1994 - 1996	Mentor- Summer Research Enrichment Program University of Nebraska Medical Center Omaha, NE (Program terminated)
1993 - 1996	Mentor- The Minority and Women Health Research Initiative University of Nebraska Medical Center Omaha, NE (Program terminated)
1987 - 1989	Medical Advisor- The Committee on Special Education-  AIDS Related Issues Connetquot Central School Districts of Islip and Miller Place Long Island, NY

Teaching Activities
Courses Co-Organized:
1995-1999	The Molecular Biology of Viruses - PAMM 890  University of Nebraska Medical Center Omaha, NE
Lecturer:
Active courses
Past courses
2005 - 2008	Management of the High Risk Neonate – COM NRSG 831 “Early Onset Neonatal Infections” University of Nebraska Medical Center Omaha, NE
2005 - 2008	Management of the High Risk Neonate – COM NRSG 831 “Neonatal Herpes Simplex and Enteroviral Infections” University of Nebraska Medical Center Omaha, NE
2002 - 2008	Clinical Research Symposium for Fellows University of Nebraska Medical Center Omaha, NE
2000 - 2008	Pulmonary/Endocrine Core Course - M-ID 641 “Pediatric Respiratory Tract Viral Infections” University of Nebraska Medical Center Omaha, NE
1997 - 2008	Introduction to Disease Processes - M-ID 630 “Vial Exanthems” University of Nebraska Medical Center Omaha, NE
1996 - 2008	Applied Pharmacology for Advanced Practice Nurses – NU 883 University of Nebraska Medical Center - College of Nursing Omaha, NE
1996 - 2008	Neurology/Ophthalmology/Psychology - Core 7 Course  University of Nebraska Medical Center Omaha, NE
1993 - 2008	Microbiology and Pathology - M-ID-630  “Bacterial Meningitis and Brain Abscess” University of Nebraska Medical Center Omaha, NE
1993 - 2008	Microbiology and Pathology - M-ID-630  “Viral Encephalitis and Meningitis” University of Nebraska Medical Center Omaha, NE
1993 - 2008	Pediatric Clerkship Combined Department of Pediatrics Creighton University and University of Nebraska Medical Center Omaha, NE
1997 - 2006	Infectious Disease System (Inter-Departmental) - IDC 233 “Picornaviruses and Their Diseases”  Creighton University School of Medicine Omaha, NE
2002 - 2005	Speaker- Cultural Competency Workshop for the Health Professional Rural Health Education Network University of Nebraska Medical Center Omaha, NE
2000 - 2005	Advanced Pediatric Course – PDT 473 Creighton University School of Medicine Omaha, NE
2000 - 2005	Pediatric/Aging Core Course – IDC 231 Creighton University School of Medicine Omaha, NE
2003	Public Health & Bioterrorism/Related Disasters Course Masters in Public Health Program University of Nebraska Medical Center and University of Nebraska at Omaha Omaha, NE
2000	Introduction to Computational Molecular Biology- PAMM 950B  University of Nebraska Medical Center Omaha, NE
1993 - 1997	Medical Microbiology and Immunology - MIC 221 Creighton University School of Medicine Omaha, NE
1992	Plagues, People, and Microorganisms - MCDB 1030  University of Colorado at Boulder Boulder, CO
1989 - 1993	Infectious Diseases Child Health Associate Program, University of Colorado Health Sciences Center Denver, CO
1987 - 1989	Medical Microbiology Department of Microbiology, School of Medicine,  State University of New York at Stony Brook Stony Brook, NY
1987 - 1989	Developmental Physiology of the Perinatal Period Department of Pediatrics, School of Medicine,  Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
1986 - 1989	Newborn Intensive Care Unit Nursing Orientation University Hospital at Stony Brook, State University of New York at Stony Brook Stony Brook, NY
1985 - 1989	Clinical Pharmacology for Graduate Nurses (HBH 535) Department of Pharmacological Sciences,  Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
1983-1989	Clinical Medicine Course- Pediatric Unit  Physician's Assistant Program, School of Allied Professions Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
1983 - 1989	Pediatric Intensive Care Lecture Series Department of Pediatrics, School of Medicine, Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
1982 - 1989	Pediatric Year III Clerkship Lectures Department of Pediatrics, School of Medicine,  Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY
Preceptor:
1984 - 1989	Pediatric Year III Clerkship Outpatient Care Coram Health Center Coram, New York
1980 - 1989	Introduction to Clinical Medicine- Pediatric Session Group School of Medicine, Health Sciences Center, State University of New York at Stony Brook Stony Brook, NY

Supervision of Graduate Students/Thesis Committees
Supervision of Undergradute/Graduate Students/Post-Graduate Fellows and Residents-University of Nebraska Medical Center:
2006 - Present	--------------------------------------------------------- ------------------------------------------------------ --------------------------------------
2001 - 2003	--------------------------------------------- ---------------------------- ------------------------------------------------------------- ---------------------
2001 - 2003	---------------------------------------------------------- ---------------- ------------------------------- -----------------------
1999 – 2001	------------------------------------------ ---------------- -------------------------------------------------------- ---------------------------
1999 - 2002	------------------------------------------------------------------- ------------------------ ----------------------------------------------- ------------------
2001	--------------------------------------------------------------- ------------------------ ----------------------------------------------- ------------------------
1996 - 2000	-------------------------------------------------------------------------- ------------------------ ----------------------------------------------- -------------------
1996 - 1998	------------------------------------------------------------------ ------------------------ ----------------------------------------------- ------------------
1994 - 1995	------------------------------------------- ---------------------------- -------------------------------------------------- ---------------------
Member of Thesis Committee - University of Nebraska Medical Center:
2001 - 2002	--------------------------------------------------------
1995 - 1999	-------------------------------------------------------------------
1994 – 1997	-----------------------------------------------------------------------
Member of Thesis Committee - Creighton University:
1.95-6.96	---------------------------------------------------------------------
Faculty Preceptor/Mentor – Medical Students and Residents:
2006-2008	------------------------------------------------------
2006-2008	------------------------------------------------------
8.2005-3.2006	------------------------
2004-2006	-------------------------------------------------------

Publications

1. ----------------------------------------------------------------------------------------------------------------------------
2. --------------------------------------------------------------------------------------------------
3. ---------------------------------------------------------------------------------------------------------------------------------------------------------
4. --------------------------------------------------------------------------------------------------------------------------------------------------
5. --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
6. ----------------------
7. Varman MV, Romero JR.Cusick RA, Esposito PW, Armstrong D. Polymicrobial wound infection and nerve injury secondary to a non-human primate bite. Infect Med. 2008;25:120-127.
8. Romero JR. Group B Coxsackievirus Infections in Children. Curr Top Microbiol Immunol 2008;323:223-240.
9. Kimberlin DW, Acosta EP, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud GA, Lakeman FD, Whitley RJ; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease. J Infect Dis. 2008;197:836-849.
10. Romero JR, Barton L. Arboviruses. In Barton LL, Friedman NR (Eds.) Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases.Humana Press. Springer Berlin Heidelberg New York, 2008;83-105.
11. Romero JR. Orthopoxviruses. In Barton LL, Friedman NR (Eds.) Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases.Humana Press. Springer Berlin Heidelberg New York, 2008;151-156.
12. Romero JR, Varman M, Barton L.Togaviruses. In Barton LL, Friedman NR (Eds.) Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases.Humana Press. Springer Berlin Heidelberg New York, 2008;105-121.
13. Newland JG, Romero JR. Myxoviruses.In Barton LL, Friedman NR (Eds.) Neurologic Manifestations of Pediatric Infectious and Immunologic Diseases.Humana Press. Springer Berlin Heidelberg New York, 2008;41-68.
14. Acosta EP, Brundage RC, King JR, Sánchez PJ, Sood S, Agrawal V, Homans J, Jacobs RF, Lang D, Romero JR, Griffin J, Cloud G, Whitley R, Kimberlin DW; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.Clin Pharmacol Ther. 2007;81(6):867-72.
15. Jafri HS MD, Ramilo O,Makari D, Charsha-May D, Romero JR.Diagnostic virology practices for respiratory syncytial virus (RSV) and influenza virus among children in the hospital setting: a national survey. Pediatr Infect Dis J 2007;26:956-58.
16. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, Kemble G, Connor EM; CAIV-T Comparative Efficacy Study Group: Romero JR. Live attenuated versus inactivated influenza vaccine in infants and young children.N Engl J Med.2007;356:685-96.
17. Truemper EJ, Romero JR. West Nile virus.Pediatr Annals. 2007;36:414-22.
18. Mix AC, Romero JR. Central Nervous System Infections.In Zaoutis LB, Chiang VW (ed), Comprehensive Pediatric Hospital Medicine.Mosby-Elsevier. Philadelphia, PA, 2007;340-351.
19. Romero JR. Entroviruses and parechoviruses. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, M. A. Pfaller (ed), Manual of Clinical Microbiology, 9th ed. American Society for Microbiology, Washington, DC, 2006;1392-1404.
20. Romero JR and Newland JG.Diagnosis of viral encephalidites: Zoonotic-associated viruses.In Concise Reviews in Pediatric Infectious Diseases, Pediatr Infect Dis J. 2006;25:741-743.
21. Newland JG and Romero JR. Diagnosis of viral encephalidites: NonZoonotic-associated viruses.In Concise Reviews in Pediatric Infectious Diseases, Pediatr Infect Dis J. 2006;25(8):739-41.
22. Romero JR. Enteroviruses (Coxsackieviruses, Echoviruses and Numbered Enteroviruses) and Parechoviruses.In Antimicrobial Therapy and Vaccines, Volume II
23. Varman M, Romero JR, Cornish NE, Manley J, Meza JL, Zach TL, Chartrand SA.Characterization and mechanisms of resistance of group B streptococcal isolates obtained at a community hospital.Euro J Clin Microbiol Infect Dis 2005; 24:431-433.
24. Romero JR, Stacy RD.Minority Behavioral Risk Factor Survey in Douglas County: A Special Report to Nebraska Office of Minority Health.A collaborative report with Douglas, Sarpy/Cass County, Nebraska Health Departments, Urban League of Nebraska, Chicano Awareness Center, University of Nebraska Medical Center, and University of Nebraska at Omaha.August 2004;1-34.
25. Romero JR, Kimberlin DW.Molecular diagnosis of viral infections of the central nervous system.Clin Lab Med 2003; 23:843-865.
26. Romero JR, Newland JG. Viral Meningitis and Encephalitis: Traditional and emerging viral agents. Semin Pediatr Infect Dis2003;14: 72-82.
27. Palivizumab Outcomes Registry Study Group*. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: Results from the palivizumab outcomes registry.Pediatr Pulm 2003;35:484-489. *Dr. Romero is a member of the writing committee.
28. Dunn JJ, Bradrick SS, Chapman NM, Tracy SM, Romero JR. The stem loop II within the 5’ nontranslated region of clinical Coxsackievirus B3 genomes determines cardiovirulence phenotype in a murine model.J Infect Dis 2003;187:1552-1561.
29. Abzug MJ, Cloud G, Bradley J, Sanchez P, Romero J, Powell D, Lepow M, Mani C, Capparelli EV, Blount S, Lakeman F, Whitley RJ, Kimberlin DW and the Collaborative Antiviral Study Group.Double blind, placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003;22(4):335-41.
30. Newland JG, Romero JR, Varman M, Drake C, Holst A, Safranek T, Subbarao K. Encephalitisassociated with influenza B infection in two children and a review of the literature.Clin Infect Dis 2003;36:e87-95.
31. Romero JR, Rotbart HA. Enteroviruses. In P. R. Murray, E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed), Manual of Clinical Microbiology, 8^th ed. American Society for Microbiology, Washington, D. C. 2003; 1427-1438.
32. Romero JR. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998-2002. Results from four years of palivizumab usage. Pediatr Infect Dis J 2003;22(2) Suppl:46-54.
33. Tracy S, Drescher KM, Chapman NM, Kim KS ,Carson SD, Pirruccello S, Lane PH, Romero JR, Leser JS.Toward testing the hypothesis that group B coxsackieviruses (CVB) trigger insulin-dependent diabetes: Inoculating NOD mice with CVB markedly lowers diabetes incidence.J Virol 2002;76(23):12097-12111.
34. Romero JR, Newland JG.Enteroviruses (Polioviruses, coxsackieviruses, echoviruses and numbered enteroviruses).In Antimicrobial Therapy and Vaccines.Lippincott, Williams and Wilkins.2002:1167-1175.
35. Romero JR. Diagnosis and management of enteroviral infections of the central nervous system.Curr Infect Dis Rep 2002, 4:309-316.
36. Kimberlin DW, Lin CY, Jacobs RF, et al., and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Natural history of neonatal herpes simplex virus infections.Pediatrics 2001;108(2):223-229. (Dr. Romero is a member of the CASG study group.)
37. Kimberlin DW, Lin CY, Jacobs RF, et al., and the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections.Pediatrics 2001;108(2):230-238.(Dr. Romero is a member of the CASG study group.)
38. Bradrick SS, Lieben EA, Carden BM, Romero JR. A predicted secondary structural domain within the internal ribosome entry site of echovirus 12 mediates a cell type specific block to viral replication.J Virol 2001;75(14):6472-6481.
39. Willis TMS, Hopp RJ, Romero JR, Larsen PD.The protective effect of brachial plexus palsy in Purpura fulminans.Pediatr Neurol2001;24(5):379-381.
40. Rotbart HA, Webster AD, Pleconaril Treatment Registry Group. Treatment of potentially life-threatening enterovirus infections with pleconaril.Clin Infect Dis 2001;32:228-235. (Dr. Romero is a member of the registry group)
41. Romero JR. Enteroviruses in humans. Encyclopedia of Life Sciences, Nature Publishing Group, London: www.els.net. 2001: 1-7.
42. Bradrick SS and Romero JR. Polioviruses. Encyclopedia of Life Sciences, Nature Publishing Group, London: www.els.net. 2001: 1-7.
43. Parasuraman TV, Frenia K, Romero JR. Enteroviral meningitis: Cost of illness and considerations for the economic evaluation of potential therapies.Pharmacoeconomics 2001;19(1):3-12.
44. Romero JR. Pleconaril: A novel antipicornaviral drug.Exp Opin Investig Drugs 2001;10(2):369-379.
45. Willian S, Tracy S, Chapman N, Leser S, Romero JR, Shapiro B, Currey K.Mutations in a conserved enteroviral RNA oligonucleotide sequences affect positive strand viral RNAsynthesis.Arch Virol 2000;145(10), 2061-2086.
46. Dunn JJ, Romero JR, Wasserman R, Rotbart HA.Stable enterovirus genome over a seven-year period in a patient with agammaglobulinemia and chronic infection.J Infect Dis 2000;182:298-301.
47. Parasuraman TV, Deverka PA, Toscini MR, on behalf of the Meningitis Consensus Panel. Estimating the economic impact of viral meningitis in the United States.Infect Med 2000;17:417-427.(Dr. Romero is a member of the consensus panel)
48. Dunn JJ, Chapman N, Tracy S, Romero JR. Genomic determinants of cardiovirulence in coxsackievirus B3 clinical isolates: Localization to the 5’ nontranslated region.J Virol2000;74:4787-4794.
49. Romero JR. Reverse transcription-polymerase chain reaction detection of the enteroviruses: Overview and clinical utility in pediatric enteroviral infections.Arch Pathol Lab Med 1999;123:1161-1169.
50. Romero JR. Enteroviruses: Diagnosis, screening, and surveillance.Infect Med 1999;16 (Suppl D):11-20.
51. Heuermann KG, Romero JR, Abromowitch MA, Gordon BG, Gross TG.Fatal coagulase negative staphylococci infection after bone marrow transplantation in a patient with persistent adverse reactions to vancomycin.Am J Pediatr Hematol/Oncol 1999;21:80-81.
52. Rotbart HA, Brennan PJ, Fife KH, Romero JR, et al.Enterovirus meningitis in adults.Clin Infect Dis 1998;27(4):896-898.
53. Boken DJ, Romero JR, and Cavalieri SJ.Sphingomonas paucimobilis bacteremia: Four cases and review of the literature.Infect Dis Clin Prac 1998;7:286-291.
54. Romero JR, Price C and Dunn JJ.Genetic divergence among the group B coxsackieviruses.Curr Top Microbiol Immunol1997;223:81-96.
55. Chapman NM, Romero JR, Pallansch MA, Tracy S.Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3.J Med Virol 1997;52: 258-61.
56. Tracy S, Chapman NM, Romero JR and Ramsingh AI.Genetics of coxsackievirus B cardiovirulence and inflammatory heart muscle disease.Trends Microbiol 1996; April.
57. Tracy S, Chapman N, Ramsingh A, Romero J, Curry K, Shapiro B, Barry W, Chin T and Hufnagel G.Coxsackievirus genetics and the cardiovirulent viral phenotype.In:Schultheiss and Schwimmbeck (eds).The Role of Immune Mechanisms in Disease.Springer-Verlag, Berlin.1996, 27-34.
58. Romero JR, Chapman NM, Rotbart HA, and Tracy SM.Polymerase chain reaction detection of the human enteroviruses.In:Becker Y and Darai G (eds)PCR: Protocol for Diagnosis of Human and Animal Virus Diseases.Berlin: Springer-Verlag, 1996, 259-266.
59. Ehrhardt AF, Sanders CC, Romero JR, Leser JS.Sequencing and analysis of four new Enterobacter ampD alleles.Antimicrob Agents Chemother 1996;40(8), 1953-1956.
60. Tu Z, Chapman NM, Hufnagel G, Tracy S, Romero JR, Barry WH, Zhao L, Currey K, Shapiro B.The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region.J. Virol. 1995;69(8):4607-4618.
61. Rotbart HA and Romero JR. Laboratory diagnosis of enterovirus infections.In:Rotbart HA (ed) Human Enterovirus Infections.Washington DC: ASM, 1995, 401-418.
62. Romero JR and Rotbart HA.Sequence analysis of the downstream 5' nontranslated region of seven echoviruses with different neurovirulence phenotypes.J. Virol.1995;69:1370-1375.
63. Romero JR. Pediatric tuberculosis.Current Opinion in Infectious Diseases. 1994;7:374-381.
64. Romero JR and Rotbart HA.Polymerase chain reaction strategies for the detection of the human enteroviruses.In: Ehrlich GD and Greenberg SJ (eds)PCR-Based Diagnostics of Infectious Organisms.Boston: Blackwell Scientific Publications, 1994:341-374.
65. Romero JR and Ogle JW.Arboviral infections in the US: Encephalitis, Colorado tick fever and hantavirus.Seminars in Pediatric Infectious Diseases.1994;5:95-101.
66. Levin MJ and Romero JR. Infections: Viral and Rickettsial.In:Hay WW, Jr., Groothuis JR, Hayward AR, and Levin MJ (eds).12th Edition, Current Pediatric Diagnosis and Treatment.Norwalk: Appleton and Lange, 1994, 1020-1053.
67. Romero JR and Rotbart HA.Polymerase chain reaction detection of the human enteroviruses.In: Persing DH, Smith TF, Tenover FC and White TJ (eds) Diagnostic Molecular Microbiology: Principles and Applications.Washington DC: American Society for Microbiology Publications, 1993:401-406.
68. Romero JR. Tick-borne diseases of the United States.Contagious Comments 1992;12:1-5.
69. Doski JJ, Priebe CJ, Jr., Driessnak-Hill M, Smith T, Kane P, Romero J. Corticosteroids in management of unresectable plasma cell granuloma (inflammatory psuedotumor) of the lung.J. Pediatr. Surg. 1991;26:1064.
70. Biancaniello TM and Romero, JR. Bacterial endocarditis after adjustment of orthodontic appliances. J. Pediatr. 1991;118:248.

Books or Journals Edited

1999-2001 Medical Editor, eMedicine Pediatric Infectious Diseases. www.eMedicine.com

Published Audiovisual/Electronic Education and CME Materials

1. Truemper EJ, Romero JR.West Nile virus.Pediatr Annals. 2007;36:414-22.
2. Romero JR. The Burden of RSV Disease. Interactive Network for Continuing Education, 2003. CD-ROM.
3. Romero J.Enteroviruses.Poxviruses and other febrile vesicular rash illness diagnostic testing meeting. Centers for Disease Control and Prevention, 2002.CD-ROM
4. Sawyer MH, Abzug MJ, Romero J.Enterovirus sepsis and meningitis. AAP-Pediatric Update, American Academy of Pediatrics,2000, 21.Audiocassette.

Abstracts

1. D. Witt, M. Marcon, J. Romero, M. Sawyer, G. Storch, J. Dunn, D. Schnurr, W. Kok. Multi-Center Evaluation of a Real Time NASBA Best for Detection of Enterovirus in Cerebrospinal Fluid From Pediatric Patients. 24th Annual Clinical Virology Symposium, 2008.
2. Herrera V, Babcock B, Bastola DR, Romero JR, Gebhart C.Performance evaluation of an in-house enterovirus assay over a two year period.22nd Annual Clinical Virology Symposium, 2006.
3. Bastola DR, Romero JR. Molecular epidemiology of Coxsackievirus B3 (CBV3) in the United States: 1949-1998.24^th Annual Meeting of the American Society for Virology, 2005.Abstract W27-8.
4. Ramilo O, Romero JR, Jafri H, Makari D, Charsha-May D.Diagnostic testing for respiratory syncytial virus and influenza in the hospital setting:A national survey.American Academy of Pediatrics National Conference and Exhibition, 2004.Section on Hospital Care: Abstract 356.
5. Newland JG, Romero JR. Examination of the plasticity of the puff binding region of Coxsackievirus B3 (CVB3).American Academy of Pediatrics National Conference and Exhibition, 2004.Section on Residents.
6. Romero JR, Ramilo O, Jafri H, Makari D, Charsha-May D.Diagnostic virology practices for respiratory virus (RSV): Comparison between teaching and non-teaching hospitals caring for children. 42^nd Annual Infectious Diseases Society of America Meeting, Program and Abstracts, 2004; pg 129; Abstract 471.
7. Romero JR, Allensworth CD, Pour AM.Experience with limited Phase I smallpox vaccination in a Midwestern children’s hospital.Pediatric Research, 2004:55:4 (part 2); 339A, Abstract 1931.
8. Romero JR, Cohen A, Boron M, Rankin M, and Synagis Outcomes Registry Study Group.Respiratory Syncytial Virus (RSV) prophylaxis in minority populations; results from the Palivizumab Outcomes Registry 2002-2003.Pediatric Research, 2004;55:4 (part 2); 237A, Abstract 1344.
9. Romero JR, Allensworth C, Pour, AM.Evaluation of phase I vaccination in Douglas County, Nebraska.41^st Annual Infectious Diseases Society of America Meeting, Program and Abstracts, 2003; pg 173; Abstract 829.
10. Varman M, Romero JR, Cornish, NE, Yam, PA.Time to detection of respiratory viruses using mixed cell shell vial cultures: 2 vs. 5 days.41^st Annual Infectious Diseases Society of America Meeting, Program and Abstracts, 2003; pg 92; Abstract 341.
11. Newland JG, Romero JR, Sarica A, Lych JC.Impact of PCR detection of enteroviral (EV) infection of the management of febrile neonates.Pediatric Research, 2003;53:4 (part 2); 320A, Abstract 1828.
12. Newland JG, Romero JR, Sarica A, Zach TL, Linder K.Spectrum of neonatal enteroviral disease over an 8-year period.40^th Annual Infectious Diseases Society of America Meeting, Program and Abstracts, 2002; pg 50; Abstract 34.
13. Varman M, Cornish NE, Zach TL, Romero JR. Changing susceptibility of group B Streptococcus from a community hospital in a mid-sized Midwestern city.Pediatric Research, 2002;41 part 2, Abstract 1537.
14. Newland JG, Romero JR, Subbarao K, Safranek T.Encephalitis associated with influenza B infections: A case series in children.39^th Annual Infectious Diseases Society of America Meeting, Program and Abstracts, 2001; pg 66; Abstract 159.
15. Boyd ZS, Bradrick SS, Cornish N, Carden BM, Romero JR. Mutations within the IRES of echovirus 12 confer a novel pathogenic phenotype to and echovirus 12-coxsackeivirus B3 chimera. 30^th Annual Meeting of the American Society for Virology, 2001, Abstract W49-9.
16. Romero JR. Pleconaril therapy of enteroviral infections in adults and children.Inter J Antimicrob Agents, 2001;17(Suppl 1),S8.04.
17. Romero JR, Bures E, Bradrick S, Price C.Molecular epidemiology of coxsackievirus B3 in the United States: 1949-1998.Pediatric Research, 2001;49 part 2, 1436.
18. Bradrick SS, Carden BM, Dunn JJ, Romero JR. Further mapping of the coxsackievirus B3 (CVB3) 5’ nontranslated region (5’NTR) cardiovirulence determinant.29th Annual Meeting of the American Society for Virology, 2000, Abstract W4-10.
19. Romero JR, Tracy SM, Chapman NM, Dunn JJ.Identification of the major determinant of cardiovirulence of coxsackievirus B3.Pediatric Research, 2000;47 part 2, 1621.
20. Romero JR, Bradrick SS, Schnurr D, Oberste S, et al.Coxsackievirus B3 (CVB3) genotypes in the United States (US).37^thAnnual Infectious Diseases Society of America Meeting, Program and Abstract, 1999; pg 164; Abstract 714, CID publishing number 703.
21. Sawyer MH, Saez-Llorenz X, Aviles CL, O’Ryan M, Romero JR. Oral Pleconaril reduces the duration and severity of enteroviral meningitis in children.Pediatric Research, 1999;45 part 2, 173A.
22. Romero JR, Schnurr D, Oberste MS, Bradrick SS, et al. Molecular epidemiology of coxsackievirus B3 (CVB3) in the United States--1954-1979.18th Annual American Society for Virology Scientific Program, 1999; Abstract W50-2.
23. Dunn JJ, Tracy SM, Chapman NM, Romero JR. Determinants of cardiovirulence in coxsackievirus B3 (CVB3) clinical isolates localize to the 5’ nontranslated regions (5’NTR).18^th Annual American Society for Virology Scientific Program, 1999; Abstract W11-6.
24. Bradrick SS, Lieben EA, Romero JR. Nonreceptor determinants of growth restriction reside within the echovirus 12 5’ nontranslated region.18^th Annual American Society for Virology Scientific Program, 1999; Abstract W30-12.
25. Romero JR, Gross T, Abromowitch M, Jung L.Pleconaril treatment of vaccine-acquired poliovirus.Pediatric Research, 1999;45 part 2: 173A.
26. Romero JR, Dunn JJ, Tracy SM, et al.Cardiovirulence determinants among naturally occurring isolates of coxsackievirus B3 reside within the 5’ nontranslated region.Pediatric Research, 1999; 45 part 2: 172A.
27. Modlin J, Reiss M, Romero J, et al.Estimating the economic impact of viral meningitis in the United States.International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, 1999; Abstract TPIL6.
28. Modlin J, Reiss M, Romero J, et al.Development and validation of a decision analytic framework to evaluate the economic impact of suspected meningitis.International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Meeting, 1999; Abstract PID10.
29. Romero JR, Magelli M, Hinrichs S, et al.Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children results in reduced health care expenditures.36^th Annual Infectious Diseases Society of America Meeting Program and Abstracts, 1998; pg 201:Abstract 668.
30. Romero JR, Kirk C, Dunn J, et al.Molecular and phenotypic characterization of a myocarditic coxsackievirus B3 (CVB3) isolate.36^th Annual Infectious Diseases Society of America Meeting Program and Abstracts, 1998; pg 134: Abstract 314.
31. Romero JR, Hinrichs S, Perry D, Kruger R and Magelli M.Reverse transcription-polymerase chain reaction diagnosis of enterovirus infections in febrile children reduces duration of hospitalization, antibiotic administration and results in reduced health care costs.15^th Annual Meeting of the Minority Medical Faculty Development Program, 1998.
32. Romero JR, Hinrichs S, Perry D, et al.Impact of reverse transcription-polymerase chain reaction diagnosis of enterovirus infections on the care of febrile children.Pediatric Research 1998; 43 part 2:156A.
33. Dunn JJ, Tracy SM, Romero JR. The 5’ untranslated region (5’UTR) of a wild-type coxsackievirus B3 (CBV3) strain attenuates the cardiovirulent phenotype of CBV3/20.17th Annual American Society for Virology Scientific Program, 1998.
34. Romero JR, Lieben E, Tracy SM, et al.Echovirus-coxsackievirus chimeras for the evaluation of the role of the echovirus 5’ nontranslated region (5’NTR) in pathogenesis Pediatric Research 1997; 41 part 2:129A.
35. Romero JR, Dunn JJ, Leser JS, et al.Complete capsid amino acid sequences of 14 wild-type coxsackievirus B3 (CBV3) isolates.16^th Annual American Society for Virology Scientific Program and Abstracts 1997:P14-4.
36. Tracy S, Chapman N, Romero J, Currey K, Shapiro B.Mutations at position 234 in coxsackieviral 5’NTR.15^th Annual American Society for Virology Scientific Program and Abstracts 1996:118.
37. Rotbart HA, Brennan PJ, Fife, KH, Romero JR, et al.Enterovirus (EV) meningitis (M) in adults.36^th Interscience Conference on Antimicrobials Agents and Chemotherapy Abstracts, 1996;170-H3.
38. Romero JR, Tracy SM, Pong AL, Hinrichs SH, Leser JS.Genetic diversity and molecular epidemiology among coxsackievirus B2 (CVB2) during a community outbreak.Pediatric Research 1996; 39 part 2:184A.
39. Romero JR, Tracy SM, Chapman NM, Leser JS.Chimeric coxsackievirus B3 as a vehicle to study the echovirus 5’ nontranslated region (5’NTR).15^th Annual American Society for Virology Science Scientific Program and Abstracts 1996:118.
40. Romero JR, Hinrichs SH, Cavalieri SJ, Perry D, Leser JS, Onyeuku J. Potential health care cost savings from PCR-based rapid diagnosis of enteroviral meningitis.Pediatric Research 1996;39 part 2:139A.
41. Romero JR, Leser JS, Tracy S, Chapman N and Winters D.Amino acid sequence variation in the major surface loop (VP2 E-F) of the cell receptor site from 8 clinical isolates of coxsackievirus B3.Pediatric Research 1995;37 part 2:187A.
42. Ehrhardt A, Sanders C, Romero JR, Leser J.Sequencing and analysis of 4 new Enterobacter ampD alleles.Interscience Conference on Antimicrobial Agents and Chemotherapy 1995:C69.
43. Chapman N, Tu Z, Hufnagel G, Tracy S, Romero J, Barry W, Zhao L, Currey K.Determination of genetics and mechanism of coxsackievirus B3 cardiovirulence.95^th General Meeting of American Society for Microbiology 1995.
44. Romero JR, Tracy S, Chapman N, and Gauntt C.Genetic variation in coxsackievirus B3 genomes.13^th Annual American Society for Virology Scientific Program and Abstracts 1994: P47-11.
45. Romero JR and Rotbart HA.Sequence diversity among enteroviruses with different neurovirulence phenotypes.Pediatric Research 1993;33 part 2:181A.
46. Romero JR and Rotbart HA.Selective amplification and partial sequence analysis of the 5'NTR of seven enteroviruses with different neurovirulence phenotypes.12^th Annual American Society for Virology Scientific Program and Abstracts 1993:A37.
47. Romero JR and Rotbart HA.Discriminant enteroviral replication in U937 cells: a candidate model for monocyte/enterovirus interactions. 30^th Interscience Conference on Antimicrobial Agents and Chemotherapy Program and Abstracts 1990;30:291.
48. Romero JR, Putnak R, Wimmer E.Enteroviral capsid protein VP3 as a group antigen for the enteroviruses.Pediatric Research 1988;23 part 2:380A.
49. Wimmer E, Kuhn RJ, Toyoda H, Nicklin MJH, Diamond DC, Murray MG, Romero, J. Chemical and biologic properties of the poliovirion.Biologic Chem, Hoppe-Seyler 1986.
50. Romero JR, Putnak R, Wimmer E.The use of poliovirus proteins VP3 and 2C as group antigens for the detection of enteroviral infections by indirect immunofluorescence.Pediatric Research 1986;20:319A.

Genbank Submissions

1. Romero JR.Poliovirus type 2 (Sabin strain) partial 5’NTR sequence of a neurorevertant isolate. Accession number: AF261763.April 28, 2000
2. Romero JR and Dunn JJ.Coxsackievirus B3 (AS strain) 5’NTR. Accession number: AF169670. July 16, 1999
3. Romero JR and Dunn JJ.Coxsackievirus B3 (AS strain) capsid coding sequences.Accession number AF169671. July 16, 1999
4. Dunn JJ and Romero JR.Coxsackievirus B3 (CO strain) 5’NTR. Accession number: AF169665. July 16, 1999
5. Dunn JJ and Romero JR.Coxsackievirus B3 (CO strain) capsid coding sequences.Accession number AF169666. July 16, 1999
6. Romero JR and Rotbart HA.Echovirus 11 5’URT.Accession number: U11705.May 20, 1995
7. Romero JR and Rotbart HA.Echovirus 12 5’URT.Accession number: U11706.May 20, 1995
8. Romero JR and Rotbart HA.Echovirus 2 5’URT.Accession number: U11707.May 20, 1995
9. Romero JR and Rotbart HA. Echovirus 4 5’URT.Accession number: U11708.May 20, 1995

Presentations, Conferences, invited Lectures
International

1. Workshop on Health and Migration: Chronic and Emerging Diseases.At the Fourth Annual Binational Policy Forum on Migration and Health, León, Guanajuato, Mexico, October 12, 2004.
2. eynote address: Pleconaril for the treatment of enterovirus infections.Presented at the Chang Gung Children’s Hospital 10^thAnniversary Symposium Enterovirus 71 in Taiwan: Past and Future, Taipei, Taiwan, March 29, 2003.
3. Identification of a genomic determinant of cardiovirulence for clinical isolates of coxsackievirus B3.Presented at the Chang Gung Children’s Hospital 10^th Anniversary Symposium Enterovirus 71 in Taiwan: Past and Future, Taipei, Taiwan, March 29, 2003.
4. Respiratory syncytial virus: A review of its molecular virology and clinical aspects.Presented at Pediatric Grand Rounds Chang Gung Children’s Hospital, Taipei, Taiwan, March 28, 2003.
5. RSV: Outcomes data.Presented at the International Congress on Respiratory Syncytial Virus, Washington, DC, June 22, 2002.
6. Pleconaril therapy of enteroviral infections in adults and children.Presented at the 22^nd International Congress of Chemotherapy, Amsterdam, The Netherlands, June 30, 2001.
7. The 5’ Untranslated Region (5’UTR) of a Wild-Type Coxsackievirus B3 (CBV3) Strain Attenuates the Cardiovirulent Phenotype of CBV3/20.Presented at 17^th Annual Meeting of the American Society for Virology, University of British Columbia, Vancouver, BC, Canada, July 13, 1998.
8. Chimeric coxsackievirus B3 as a vehicle to study the echovirus 5’ nontranslated region (5’NTR).Presented at the 15^th Annual American Society for Virology Meeting, New London, Ontario, Canada, July 14, 1996.
9. Pediatric AIDS.Presented at the conference on Tópicos Selectos en Infectología Pediátrica (Selected Topics in Pediatric Infectious Diseases) held by the College of Pediatrics of Nuevo Leon.Neuvo Leon, Monterrey, México. June 15-16, 1990.
10. Hepatitis E.Presented at the conference on Tópicos Selectos en Infectología Pediátrica (Selected Topics in Pediatric Infectious Diseases) held by the College of Pediatrics of Nuevo Leon.Neuvo Leon, Monterrey, México. June 15-16, 1990.

National Presentations and University Research Seminars

1. Multi-Center Evaluation of a Real Time NASBA Best for Detection of Enterovirus in Cerebrospinal Fluid From Pediatric Patients. At the 24th Annual Clinical Virology Symposium, Daytona Beach, FL April 27-30, 2008.
2. Health Disparities: Cancer and Heart Disease.Coordinator of Small Group Session at the 5^th Social Equity Leadership Conference, National Academy of Public Administration, Omaha, NE February 2-3, 2006.
3. An overview of economic and health indicators among Heartland Latinos.At the Fifth Annual Binational Health Policy Forum, Chicago, IL, October 12, 2005.
4. Diagnostic virology practices for respiratory virus (RSV): Comparison between teaching and non-teaching hospitals caring for children.Presented at the 42^nd Annual Infectious Diseases Society of America Meeting, Boston MA September 30-October 3, 2004.
5. Experience with limited Phase I smallpox vaccination in a Midwestern children’s hospital. Presented at the Pediatric Academic Societies’ Meeting, San Francisco, CA May 1-4, 2004.
6. Respiratory Syncytial Virus (RSV) prophylaxis in minority populations; results from the Palivizumab Outcomes Registry 2002-2003.Presented at the Pediatric Academic Societies’ Meeting, San Francisco, CA May 1-4, 2004.
7. Evaluation of phase I vaccination in Douglas County, Nebraska. Presented at the 41^st Annual Infectious Diseases Society of America Meeting, San Diego, CA October 9-12, 2003.
8. Time to detection of respiratory viruses using mixed cell shell vial cultures: 2 vs. 5 days. Presented at the 41^st Annual Infectious Diseases Society of America Meeting, San Diego, CA October 9-12, 2003.
9. Viral Central Nervous System Infections.Presented as part of the Microbiology Series of The University of Texas Health Sciences Center at San Antonio, TX, September 3, 2003.
10. Impact of PCR detection of enteroviral infection of the management of febrile neonates. Presented at Pediatric Academic Societies’ Meeting, Seattle, WA, May 4, 2003.
11. Spectrum of neonatal enteroviral disease over an 8-year period. Presented at the 40^th Annual Infectious Diseases Society of America Meeting, Chicago, IL, October 26, 2002.
12. Enteroviral vesiculo and papular exanthems.Presented at the CDC/APHL-sponsored Meeting on Poxvirus and other Febrile Vesicular Rash Illness Diagnostic Testing, San Diego, CA, October 1, 2002.
13. Not so wild a dream.Co-presented at the 25^th Annual Rural Health Association Meeting, Kansas City, MO, May 17, 2002.
14. Changing susceptibility of group B Streptococcus from a community hospital in a mid-sized Midwestern city.Presented atPediatric Academic Societies’ Meeting, Baltimore, MD, May 5, 2002.
15. Common viral meningoencephalidities in children. Presented at the 5^th Annual Pediatric Acute Care Symposium, The Pediatric Hospitalist Conference, Las Vegas, NV, April 4, 2002.
16. Encephalitis associated with influenza B infections: a case series in children.Presented at the 38^th Annual Infectious Diseases Society of America Meeting, San Francisco, CA, November 25-28, 2001.
17. Mutations within the IRES of echovirus 12 confer a novel pathogenic phenotype to and echovirus 12-coxsackeivirus B3 chimera. Presented at the 30^th Annual Meeting of the American Society for Virology, Madison, WI, 2001
18. Evaluation of the foreign-born adoptee: Infectious disease issues. Presented at the Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Hilton Head, NC, June 28, 2001.
19. Viral diagnostics for the practicing clinician. Presented at the Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Hilton Head, NC, June 28, 2001.
20. Hepatitis C infection in children.Presented at the Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Hilton Head, NC, June 27, 2001.
21. 0% disparity when all our children are healthy.Panelist in a discussion at meeting sponsored by CityMatch, a national organization of public health leaders, Omaha, NE, May 3, 2001.
22. Molecular epidemiology of Coxsackievirus B3 in the United States: 1949-1998.Presented at Pediatric Academic Societies’ Meeting, Baltimore, MD, April 29, 2001.
23. Use of naturally occurring coxsackievirus B3 isolates to map virulence determinants. Department of Biological Sciences, Purdue University, West Lafayette, IN, January 31, 2001.
24. Further mapping of the coxsackievirus B3 5’ nontranslated region cardiovirulence determinant.Presented at 19^th Annual Meeting of the American Society for Virology Meeting, Fort Collins, CO, July 8, 2000.
25. Identification of the major determinant of cardiovirulence of coxsackievirus B3. Presented atplatform session Pediatric Academic Societies’ Meeting, Boston, MA, May 13, 2000.
26. Coxsackievirus B3 Genotypes in the United States.Presented at 37^th Annual Infectious Diseases Society of America Meeting,Denver, CO, November20, 1999.
27. Picornaviral Infections in High-Risk Patients.Presented as part of the Satellite Symposium Advances in Management of Common Viral Infections: Meningitis to Respiratory Infection at the American College of Emergency Room Physicians annual meeting, Las Vegas, NV, October 12, 1999.
28. Molecular Epidemiology of Coxsackievirus B3 in the United States: 1954-1979. Presented at the 18^th Annual Meeting of the American Society for Virology, University of Massachusetts, Amherst, MA, July 13, 1999.
29. Cardiovirulence determinants among naturally occurring isolates of coxsackievirus B3 reside within the 5’ nontranslated region.Presented at Pediatric Academic Societies’ Meeting, San Francisco, CA, May 4, 1999.
30. Pleconaril treatment of vaccine-acquired poliovirus.Presented at Pediatric Academic Societies’ Meeting, San Francisco, CA, May 4, 1999.
31. RT-PCR for the Detection of Pediatric Enteroviral Infections.Presented at the 8^th Annual DNA Technology in the Clinical Laboratory Symposium, William Beaumont Hospital, Royal Oak, MI, March 25-27, 1999.
32. Molecular and phenotypic characterization of a Myocarditic Coxsackievirus B3 (CVB3) Isolate.Presented at 36^th Annual Infectious Diseases Society of America Meeting, Denver, CO, November 14, 1998.
33. Reverse Transcription-Polymerase Chain Reaction Diagnosis of Enterovirus Infections in Febrile Children Results in Reduced Health Care Expenditures.Presented at 36^th Annual Infectious Diseases Society of America Meeting, Denver, CO, November 13, 1998.
34. Diagnostic Needs, Screening and Surveillance of Viral Meningitis.Presented at Clinical and Pharmacologic Considerations for Viral Meningitis Roundtable, in Denver, CO, November 11, 1998
35. Update on Enteroviral Infections of Children. Presented at Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Lake Buena Vista, FL, October 16, 1998.
36. Prevention of Perinatal Transmission of HIV and Follow-up of the HIV-Exposed Infant.Presented at Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Lake Buena Vista, FL, October 16, 1998.
37. Poliovirus, Polio Vaccines and Vaccine Policy Controversies.Presented at Pediatric Infectious Disease Seminar, The Lloyd Noland Foundation, Lake Buena Vista, FL, October 15, 1998.
38. Reverse Transcription-Polymerase Chain Reaction Diagnosis of Enterovirus Infections in Febrile Children Reduces Duration of Hospitalization, Antibiotic Administration and Results in Reduced Health Care Costs.Presented at 15^th Annual Meeting of the Minority Medical Faculty Development Program, Princeton, NJ, October 8, 1998.
39. Impact of Reverse Transcription-Polymerase Chain Reaction Diagnosis of Enterovirus Infections on the Care of Febrile Children.Presented at Pediatric Academic Societies’ Meeting, New Orleans, LA, May 4, 1998.
40. Complete capsid amino acid sequences of 14 wild-type coxsackievirus B3 isolates.Presented as poster at the 16th American Society for Virology Meeting, Bozeman, MT, July 21, 1997.
41. Echovirus-coxsackievirus chimeras for the evaluation of the role of the echovirus 5’ nontranslated region in pathogenesis. Presented as platform session at the Pediatric Academic Society’s Meeting, Washington DC, May 5, 1997.
42. Genetic diversity and molecular epidemiology among coxsackievirus B2 during a community outbreak.Presented at the Pediatric Academic Societies’ Annual Meeting.Washington D.C., May 1996.
43. Potential health care cost savings from PCR-based rapid diagnosis of enteroviral meningitis. Presented at the Pediatric Academic Societies’ Annual Meeting.Washington D.C., May 1996.
44. Detection of enteroviral meningitis by molecular methods.Presented at the Pan American Society for Clinical Virology Symposium, Clearwater, FL, April 26, 1996.
45. Sinusitis: Clinical Considerations and Management.Presented at the Twenty-third Annual Physician Assistant Conference.Las Vegas, NV.May 29-June 3, 1995.
46. Amino Acid Variation in the Major Surface Loop (VP2 E-F) of the Cell Receptor From 8 Clinical Isolates of Coxsackievirus B3.Poster session presented at the Society for Pediatric Research Annual Meeting. San Diego, CA.May 7-11, 1995.
47. Genomic Variation of Coxsackievirus B3.Presented at the 13^th Annual Meeting American Society for Virology. University of Wisconsin, Madison, WI. July 9-13, 1994.
48. Pediatric Tuberculosis.Presented at the Eleventh Annual Conference on Infectious Disease.Aspen, Colorado.August 16-20, 1993.
49. Selective Amplification and Partial Sequence Analysis of the 5'NTR of Seven Enteroviruses With Different Neurovirulence Phenotypes.Romero, J.R. and Rotbart, H.A. Workshop Session presented at the 12^th Annual Meeting American Society for Virology. University of California, Davis, California. July 10-14, 1993.
50. Sequence Diversity Among Enteroviruses With Different Neurovirulence Phenotypes. Romero JR and Rotbart HA.Platform session presented at the Society for Pediatric Research Annual Meeting. Washington D.C. May 3-6, 1993.
51. Tick-Borne Diseases of the United States- Update 1992.Presented at the Tenth Annual Conference on Infectious Disease.Aspen, Colorado.August 10-14, 1992.
52. Discriminant Enteroviral Replication in U937 Cells: a Candidate Model for Monocyte/Enterovirus Interactions.Romero JR and Rotbart HA.Presented at the 30^th Interscience Conference on Antimicrobial Agents and Chemotherapy. Atlanta, Georgia.October 21-24, 1990.
53. Enteroviral Capsid Protein VP3 as a Group Antigen for the Enteroviruses.Romero JR, Putnak R, Wimmer E.Platform session presented at the Society for Pediatric Research Annual Meeting. Washington D.C. May 2-5, 1988.
54. The Use of Poliovirus Proteins VP3 and 2C as Group Antigens for the Detection of Enteroviral Infections by IndirectImmunofluorescence. Romero, J.R., Putnak, R., Wimmer, E.Poster session presented at the Society for Pediatric Research Annual Meeting. Washington D.C. May 5-8, 1986.

Regional and State (Only CME programs are listed.)

1. Diagnosis of Viral Encephalitis and Meningitis. Presented at the 2007 ASCP/CLMA/IACLS/NSCLS Spring Meeting, April 19, 2007, Council Bluffs, IA.
2. The Spectrum of Enteroviral Infections in Children.Presented at the 10^th Annual Infectious Diseases Seminar, Driscoll Children’s Hospital, October 22, 2005, Corpus Christi, TX.
3. Molecular Diagnosis of Pertussis.Presented at the Iowa/Nebraska Association for Clinical Laboratory Science Spring Conference, April 27, 2005, Council Bluffs, IA.
4. Respiratory Infections in Children.Presented at the 14^th Annual Nebraska Nurse Practitioner Conference, February 25, 2005, Kearney, NE
5. Trends in Tuberculosis: A Focus on Age, Immigration and Ethnicity.Presented in Distinguished Lecturer Series at Children’s Hospital, January 28, 2005, Omaha, NE
6. Overview of the Findings of the Douglas County Minority Behavioral Risk Survey.Keynote address presented at the 2004 Nebraska Health and Human Services Minority Health Conference, October 26, 2004, Lincoln, NE
7. Trends in Tuberculosis: A Focus on Age, Immigration and Ethnicity.Presented at the 2004 Nebraska Health and Human Services Minority Health Conference, October 26, 2004, Lincoln, NE
8. Respiratory Syncytial Virus: What’s New.Presented at the 2004 Pediatric Respiratory Update, October 19, 2004, Toledo, OH
9. Current Concepts in Pediatric Bacterial Meningitis.Presented at the Infectious Diseases Conference 2004, September 21, 2004, Sioux City, IA
10. Bioterrorism and “New” Infectious Diseases.Presented at Nebraska Association of Physicians Assistants 29^th Annual Spring CME Conference, April 16, 2004, Kearney, NE
11. SARS: Our Current Understanding.Presented at the ASCP/CLMA/NSCLS Spring Meeting, April 15, 2004, Omaha, NE
12. Group B Streptococcus and Neonatal Sepsis: A Changing Landscape.Presented at 2004 Perinatal, Neonatal Women's Health Conference, March 26, 2004, Sioux Falls, SD
13. Effectively Treating Otitis Media in Children. Presented at An Update on Adult and Pediatric Infectious Diseases, October 25, 2003, Tampa FL
14. Understanding Otitis Media in Children.Presented at Sinusitis and Otitis Media, October 25, 2003, Tampa FL
15. Resistance and Susceptibility- Influence on Treatment Decisions.Presented at Sinusitis and Otitis Media, August 9, 2003, Seattle, WA
16. Understanding Otitis Media in Children.Presented at Sinusitis and Otitis Media Conference, August 9, 2003, Seattle, WA
17. Group B Streptococcus: Changing Antibiotic Spectrum and New Screening Recommendations.Presented at the Twenty-Sixth Annual Black Hills Seminar on Advances in Clinical Pediatrics, June 12, 2003, Rapid City, SD
18. Breakfast with the Specialists: ID Potpourri.Presented at the Twenty-Sixth Annual Black Hills Seminar on Advances in Clinical Pediatrics, June 12, 2003, Rapid City, SD
19. Clinical Aspects and Prophylaxis of Respiratory Syncytial Virus Infections. Presented at the Twenty-Sixth Annual Black Hills Seminar on Advances in Clinical Pediatrics, June 11, 2003, Rapid City, SD
20. Overview of “Newer” Vaccines for Pediatric Use.Presented at the Twenty-Sixth Annual Black Hills Seminar on Advances in Clinical Pediatrics, June 11, 2003, Rapid City, SD
21. Enhancing Latino Participation in Clinical Trials.Co-presented at the Third Annual Heartland Latino Leadership Conference, Omaha, NE, November 1, 2002
22. Reaching our Minority Populations.Presented at the 2002 Nebraska Rural Health Conference, Harnessing the Winds of Change: Meeting the Challenges in Rural and Frontier Healthcare. Kearney, NE, September 4, 2002.
23. Otitis Media: Trends in Antibiotic Resistance—An Update on CDC Recommendations.Presented at Continuing Medical Education Conference, Good Samaritan Hospital, Kearney, NE, April 11, 2001.
24. Immunization Update.Presented at Nebraska Academy of Physician’s Assistants Convention, Kearney, NE, April 5, 2001.
25. Hepatitis C in Children.Presented at Practical Pediatrics: 2001 Update, Children’s Hospital, Omaha, NE, February 16, 2001.
26. Therapy of Otitis Media: CDC Recommendations.Presented at Midwinter Family Practice Conference, Nebraska Chapter of American College of Osteopathic Family Physicians, Inc., Des Moines, IA, January 12, 2001.
27. Management of HIV-infected Women & Children.Presented at Update for HIV Care Providers and Educators, University of Nebraska at Omaha, Omaha, NE, November 8, 2000.
28. Adolescent and Adult Immunizations.Presented at Nebraska Family Health Conference sponsored by the Nebraska Department of Health and Human Services, Kearney, NE, March 15, 2000.
29. Childhood Immunizations.Presented at Nebraska Family Health Conference sponsored by the Nebraska Department of Health and Human Services, Kearney, NE, March 15, 2000.
30. Pediatric Infections.Presented at Nebraska Health System Primary Care Physician Update on Infectious Diseases Program, Omaha, NE, November 5, 1999.
31. Respiratory Syncytial Virus. Presented at the 15th Annual Maternal Child Conference, Mary Lanning Hospital, Hastings, NE, April 8, 1999.
32. Antibiotic Update. Presented at the 15th Annual Maternal Child Conference, Mary Lanning Hospital, Hastings, NE, April 8, 1999.
33. Pediatric Update on Immunizations. Presented at the 15th Annual Maternal Child Conference, Mary Lanning Hospital, Hastings, NE, April 8, 1999.
34. Penicillin Resistant Pneumococcus.Presented at Infectious Disease Seminar, Faith Regional Medical Center, Norfolk, NE, October 4, 1997.
35. Antiviral Therapy. Presented at Infectious Disease Seminar, Faith Regional Medical Center, Norfolk, NE, October 4, 1997.
36. Respiratory Syncytial Virus Infection and bronchiolitis.Presented at Children’s Healthcare Symposium, Sioux Valley Hospital, Sioux Falls, SD, October 3, 1997.
37. Enterovirus Infections in Pediatrics.Presented at Children’s Health Care Symposium, Sioux Valley Hospital, Sioux Falls, SD, October 3, 1997.
38. Pediatric AIDS.Presented at Children’s Health Care Symposium, Sioux Valley Hospital, Sioux Falls, SD, October 3, 1997.
39. Antibiotics and Emerging Microbial Resistance.Presented at University of South Dakota School of Medicine’s 20^th Annual Black Hills Pediatric Seminar, Rapid City, SD, June 11-12, 1997.
40. Tick-Borne Diseases.Presented at University of South Dakota School of Medicine’s 20^th Annual Black Hills Pediatric Seminar, Rapid City, SD, June 11-12, 1997.
41. Enteroviral Infections in Pediatrics. Presented at University of South Dakota School of Medicine’s 20^th Annual Black Hills Pediatric Seminar, Rapid City, SD, June 11-12,1997.
42. Evaluation of the febrile infant less than 36 months of age with no identifiable focus.Presented at University of Nebraska Medical Center Family Practice Review Course, Omaha, NE, April 7, 1997.
43. Potpourri on infectious disease.Presented at Emergency medicine: Skills and knowledge for the practicing physician. University of Nebraska Medicine Center, Omaha, NE, September 27, 1996
44. Management of perinatal and neonatal viral infections.Presented at the Annual Nebraska Neonatal Conference.Kearney, NE, April 12, 1996.
45. Pneumococcus in the 90’s.Presented at the Nebraska Academy of Physician Assistants Annual Continuing Medical Education Convention.Grand Island, NE, April 11, 1996.
46. Evaluation of the Febrile Infant <36 Months of Age With No Identifiable Focus.Presented at Family Practice Review Course, University of Nebraska Medical Center, Omaha, NE, March 18, 1996 and April 15, 1996.
47. Emerging Organisms Related to Pediatric Infectious Diseases.Presented to the Nebraska Society of Pediatric Nurses, Omaha, NE, November 9, 1995.
48. Strategies for Treatment of Non-HIV Viral Infections. Presented at Iowa Physician Assistant Society 21^st Annual Fall Continuing Medical Education Conference, Iowa City, IA, October 4, 1995.
49. Common viral infections.Presented as part of the Great Plains Regional Medical Center’s Continuing Medical Education Program.North Platte, NE.November 21, 1994.
50. Mechanisms of Antimicrobial Resistance. Presented at the Nebraska Academy of Physician Assistants Summer Conference, Ogallala, NE, July 21, 1995.
51. Management of the febrile infant.Presented at University of Nebraska Medical Center Family Practice Review Course. Omaha, NE.April 28, 1995.
52. RSV Update. Presented at the Dakota Medical Center Fifteenth Annual Pediatric Update.Fargo, ND.April 6-7, 1995.
53. Vaccines for children.Presented at University of Nebraska Medical Center Family Practice Review Course. Omaha, NE.March 31, 1995.
54. Immunization Update 1995: A Review of the Significant Recent Immunization Successes, Shortfalls, and Future Possibilities.Presented at the Third Annual Medical Update for Primary Care Physicians.Omaha, NE. March 3, 1995.
55. RSV bronchiolits and treatments.Presented as part of the Great Plains Regional Medical Center’s Continuing Medical Education Program.North Platte, NE.November 21, 1994.
56. Sepsis in the Neonate.Presented at NICU Infections: Diagnosis, Treatment and Infection Control Conference of the Mid Plains Association of Neonatal Nurses. Omaha, NE. October 26, 1994.
57. Update on Pediatric Tuberculosis:The Latest AAP and CDC Recommendations.Seminar presented to 62nd Annual Postgraduate Assembly of the Omaha Mid-West Clinical Society. Omaha, NE. October 5, 1994.
58. Management of the Febrile Infant Less Than 36 Months of Age.Presented at Family Practice Review Course, University of Nebraska Medical Center. Omaha, NE. March 18 and April 22, 1994.
59. The Current Epidemiology of Childhood Meningitis.Presented at Infection Control Comedies and Tragedies- Ninth Symposium Sponsored by the Association for Practitioners in Infection Control.Smithtown, New York.October 29, 1993.

Grand Rounds (Only CME programs are listed.)

1. Arboviral Infections of the Central Nervous Systems.Presented at Pediatric Grand Rounds, Children’s Hospital, Omaha, NE, June 22, 2007.
2. Pertussis.Presented at Nursing Grand Rounds, Children’s Hospital, Omaha, NE, August 10, 2006
3. Viral Encephalidites of North America.Presented at the University of South Dakota School of Medicine, Department of Pediatrics Grand Rounds, Sioux Valley Hospital, Sioux Falls, SD, May 26, 2005.
4. Everything You Wanted to Know About Influenza But Didn't Know Who to Ask. Co-presented at Pediatric Grand Rounds, Children’s Hospital, Omaha, NE, December 12, 2003.
5. Perinatal Enteroviral Infections.Presented at the Obstetric and Gynecology Grand Rounds, Creighton University Medical Center, Omaha, NE, December 10, 2003.
6. Group B Streptococcus: Changing Antibiotic Spectrum and New Screening Recommendations.Presented at University of South Dakota School of Medicine, Department of Pediatrics Grand Rounds, Sioux Valley Hospital, Sioux Falls, SD, May 15, 2003.
7. Respiratory syncytial virus: A Review of its Molecular Virology and Clinical Aspects.Presented at Pediatric Grand Rounds Chang Gung Children’s Hospital, Taipei, Taiwan, March 28, 2003.
8. Lower Respiratory Tract Infections in Children.Presented at Pediatric Grand Rounds St. Elizabeth Health System, Lincoln, NE, February 25, 2003
9. Primary Immunodeficiency in Children: Evaluation of the Child with Suspected Immunodeficiency.Presented at Pediatric Grand Rounds St. Elizabeth Health System, Lincoln, NE, January 30, 2003
10. Mapping a Major Genomic Determinant of Cardiovirulence in Coxsackievirus B3. Presented at the Weibe Foundation Lecture Series, Children’s Hospital, Omaha, NE, January 24, 2003
11. Enteroviral Myocarditis: Determinants of Cardiovirulence in Coxscakievirus B3.Presented at Pediatric Grand Rounds, Mercy Children’s Hospital, Kansas City, MO, October 31, 2002.
12. Respiratory Syncytial Virus: Overview and Developments in Prophylaxis.Presented at Pediatric Grand Rounds, St. John Hospital and Medical Center, Detroit, MI, July 22, 2002.
13. Respiratory Syncytial Virus: Overview and Recent Developments.Presented at Pediatric Grand Rounds, Riley Children’s Hospital, Indianapolis, IN, January 30, 2002.
14. Hepatitis C in Children.Presented at Grand Rounds, Blank Children’s Hospital, Des Moines, IA, January 18, 2002.
15. Respiratory Syncytial Viral Infections. Altru Health System, Grand Forks, ND, October 17, 2001.
16. Respiratory Syncytial Viral Infections in Children and Adults. MeritCare Health System, Fargo, ND, October 16, 2001.
17. Hepatitis C.Presented at Pediatric Grand Rounds, Children’s Hospital, Omaha, NE, May 4, 2001.
18. Postnatal Follow Up of the HIV-Exposed Infant.Presented at Obstetrics and Gynecology Department Grand Rounds, Creighton University Medical Center, Omaha, NE, February 14, 2001.
19. Update on AIDS and HIV in Children.Presented at Pediatric Grand Rounds, University of Tennessee Medical Center, Knoxville, TN, October 19, 2000.
20. Respiratory Syncytial Virus: Trends and Treatment.Presented at Pediatric Grand Rounds, Cook Children’s Medical Center, Fort Worth, TX, August 29, 2000.
21. New Anti-Influenza Drugs: The Neuraminidase Inhibitors.Presented at Grand Rounds, Children’s Hospital Pediatric, Omaha, NE, December 10, 1999.
22. Influenza: Diagnosis and Treatment Options.Presented at Grand Rounds, Good Samaritan Hospital, Kearney, NE, December 3, 1999.
23. Respiratory Syncytial Virus Infections: Overview and New Insights.Presented at Pediatric Grand Rounds, Blank Children’s Hospital Pediatric, Des Moines, IA, October 29, 1999.
24. Overview of RSV Infections.Presented at Pediatric Grand Rounds, Wesley Medical Center, Wichita, KS, October 15, 1999.
25. Tri-Institutional Research on Enterovirus-Related Diseases.Presented at Grand Rounds, Children’s Hospital, Omaha, NE, August 6, 1999.
26. RSV and Asthma: Is there a link?Presented at Pediatric Grand Rounds, Regions Hospital, St. Paul, MN, January 29, 1999.
27. Update on Issues in Pediatric Infectious Diseases-1999.Presented at Pediatric Grand Rounds, Good Samaritan Hospital, Kearney, NE, January 22, 1999.
28. Seminar on Current Amplified Molecular Techniques in Microbiology.Presented at Grand Rounds, Children’s Hospital, Omaha, NE, April 17, 1998.
29. Enteroviral RT-PCR Significantly Impacts on the Care of Febrile Infants and Children.Presented at Grand Rounds, Children’s Hospital, Omaha, NE, August 14, 1998.
30. Pneumococcal Resistance-Molecular to Medical: An Overview.Presented at Pediatric Grand Rounds, University of Iowa School of Medicine, Iowa City, IA, February 7, 1997
31. Management of RSV infections.Presented at Grand Rounds, Olympia Fields Hospital, Olympia Fields, IL, January 28, 1997.
32. RSV-Bronchiolitis.Presented at Grand Rounds, Mercy Medical Center, Des Moines, IA, December 3, 1996.
33. RSV Overview.Presented at Grand Rounds, St. Anthony Hospital, Chicago, IL, November 22, 1996.
34. Penicillin resistant pneumococcal infections.Presented at Pediatric Grand Rounds, Butterworth Hospital, Grand Rapids, MI, April 23, 1996.
35. Management of the febrile infant: Summary of the Febrile Infant Task Force. Presented at Pediatric Grand Rounds Children’s Hospital. Omaha, NE, April 19, 1996.
36. Respiratory Syncytial Virus: An Overview.Presented at Mt. Sinai Hospital Grand Rounds, Chicago, IL, March 20, 1996.
37. Pneumococcal Resistance in the 90’s.Presented at Hackley Hospital Grand Rounds, Muskegon, MI, March 11, 1996.
38. Respiratory Syncytial Virus Update.Presented at the Bismarck Continuing Medical Education Council Grand Rounds, Bismarck, ND, March 7, 1996.
39. Antiviral Therapy. Presented at Mason City Clinic Grand Rounds, Mason City, IA, March 6, 1996.
40. PCR Diagnosis of enterovirus infections: What the clinician needs to know. Presented at Grand Rounds, Children’s Hospital, Omaha, NE, February 16, 1996.
41. The Rise of Penicillin Resistant Pneumococcal Infections.Presented at University of South Dakota School of Medicine Department of Internal Medicine Grand Rounds, Sioux Valley Hospital, Sioux Falls, SD, January 31, 1996.
42. Respiratory syncytial virus infections.Presented at Grand Rounds, Children’s Hospital.Omaha, NE.November 10, 1995.
43. RSV Related Illness and Current Treatments.Presented at Pediatric Grand RoundsSt. Mary’s Hospital, Rhinelander, WI, January 13, 1995.
44. Update on Immunizations.Presented at Grand Rounds, Children’s Hospital, Omaha, NE, May 27, 1994.

Local (Only CME programs are listed.)

1. New Pediatric Vaccines.Presented at University of Nebraska Medical Center Clarkson Hospital, Omaha, NE, October 26, 2007.
2. Winter Viral Illnesses: What’s Here and What to Expect this Winter.Presented at Alegent Health Bergan Mercy Medical Center and Lakeside Hospital, Omaha, NE, January 17 and 19, 2006
3. Review of RSV Infection in High Risk Infants.Presented at the Twelfth Newborn and Pediatric Symposium, Louisville, KY, October 22, 2004.
4. Review of the AAP/AAFP Guidelines for Treatment of Otitis Media.Presented at The Great Plains Regional Medical Center, North Platte, NE, April 22, 2004
5. Unspeakable Bugs- The STDs.Presented at the Bugs, Bumps, Boo-boos Conference-Children’s Hospital, Omaha, NE, October 29, 2003
6. The Management of Serious Infections in Children.Presented at the 9^th Annual Infectious Diseases Symposium, St. Francis Health Center, Topeka, KA, October 2, 2003.
7. Managing Pediatric Upper Respiratory Infections in an Era of Increasing Bacterial Resistance.Presented at the Platte-Loup Medical Society Meeting, Columbus, NE, September 23, 2003.
8. Smallpox Overview: Epidemiology to Prevention.Presented at the Bioterrorism Health Education Consortium Symposium, Norfolk, NE, June 10, 2003.
9. Group B beta Streptococcal Resistance Among Pregnant Women.Presented at the Mary Lanning Memorial Hospital Spring CME Conference, Hastings, NE, May 10, 2003.
10. Current Trends in Antibiotic Resistance Among S. pneumoniae and S. aureus.Presented at the Mary Lanning Memorial Hospital Spring CME Conference, Hastings, NE, May 10, 2003.
11. “Newer” Pediatric Vaccines.Presented at the Mary Lanning Memorial Hospital Spring CME Conference, Hastings, NE, May 10, 2003.
12. Smallpox: The Disease and Its Prevention.  Presented at the Mary Lanning Memorial Hospital Spring CME Conference, Hastings, NE, May 9, 2003.
13. Infectious Disease Update. Presented at Crawford County Medical Society Annual Meeting, Denison, IA, May 9, 2002.
14. Otitis Media: Trends in Antibiotic Resistance—An Update on CDC Recommendations.Presented at CME Program for Good Samaritan Health Systems, Kearney, NE, April 20, 2001.
15. Immunization Update 2001.Presented at Nebraska Academy of Physician Assistants Convention, Kearney, NE, April 5, 2001.
16. Hepatitis C in Children.Presented at Practical Pediatrics: 2001 Update, Children’s Hospital, Omaha, NE, February 16, 2001.
17. Update on Respiratory Syncytial Virus Infection in Children.Presented at CME Program for St. John’s Regional Medical Center, Joplin, MO, December 4, 2000.
18. Respiratory Syncytial Virus: Trends and Treatment.Presented at Methodist Hospital School of Nursing, Omaha, NE, November 17, 2000.
19. Overview of Community Acquired Pneumonia: Therapeutic Options.Presented to Northeast Nebraska Medical Society, Norfolk, NE, April 6, 2000.
20. Community Acquired Infection: Antibiotic Resistant Disease.Presented at Mercy Hospital, Council Bluffs, IA, March 20, 2000.
21. Respiratory Syncytial Virus Infection: Overview and New Insights.Presented at Trinity Regional Hospital, Fort Dodge, IA, January 26, 2000.
22. Newer Therapies for Influenza Virus Infection.Presented at Cass County Memorial Hospital, Atlantic, IA, December 20, 1999.
23. Respiratory Syncytial Virus Infections.Presented at Alegent Health Mercy Hospital, Council Bluffs, IA, November 30, 1999.
24. Parenteral Antibiotic Therapy in the Face of Increasing Bacterial Resistance.Presented at Carroll County Medical Society Meeting, Carroll, IA, April 26, 1999.
25. Update: Pediatric Antibiotics.Presented at Annual Pediatric Fellowship, Children’s Hospital, Omaha, NE, December 11, 1998.
26. Treatment of Acute Otitis Media in the Age of Antimicrobial Resistance.Presented to Platte-Loup Valley Medical Society, Columbus, NE, March 24, 1998.
27. Overview and Update of RSV in Pediatric Patients.Presented at AMI Culver-Union Hospital, Indianapolis, IN, December 11, 1997.
28. Emerging Antibiotic Resistance in Pneumococcal Infections.Presented at the Children’s Hospital Annual Pediatric Fellowship, Omaha, NE, November 8, 1997.
29. Drug-Resistant Streptococcus pneumoniae. Presented to Lynn County Medical Society, Cedar Rapids, IA, October 28, 1997.
30. Penicillin-Resistant Pneumococcus:Its Implications for Diagnosis and Therapy.Presented at Iowa Methodist Medical Center, Des Moines, IA, October 24, 1997.
31. Management of Otitis Media and Sinusitis in an Age of Increasing Antibiotic Resistance.Presented at Iowa Methodist Medical Center, Des Moines, IA, October 23, 1997.
32. RSV Bronchiolitis in the Pediatric Patient.Presented at Mercy Hospital Medical Center, Des Moines, IA, September 24, 1997.
33. Update on RSV.Presented at CME Program, Dakota Heartland Hospital, Fargo, ND, December 19, 1996.
34. Penicillin-Resistant Pneumococcus and Mechanisms of Antimicrobial Resistance.Presented at CME Program, San Juan Regional Medical Center, Farmington, NM, November 6, 1996.
35. Pneumococcal Resistance in the 90’s.Presented at Family Medicine CME Course, for University of Nebraska Medicine Center, in Lincoln, NE, September 28, 1996.
36. Sepsis and infection in children.Presented at the Children’s Hospital Medical-Surgical Units Review Session for Registered Nurses.Omaha, NE, August 23-30, 1996.
37. Pediatric Infectious Disease Case Presentations.Presented at Pediatric Grand Rounds Children’s Hospital. Omaha, NE, August 16, 1996.
38. Tuberculosis in the 90’s.Presented at Salina Regional Health Center.Salina, KS, July 25, 1996.
39. Penicillin Resistant Pneumococcal Infections. Presented at the Third District Medical Society and Brookings Hospital. Brookings, SD, June 20, 1996.
40. Antibiotic Resistance.Presented at Continuing Medical Education Program Pediatric Conference, Trinity Medical Center.Rock Island, IL, June 7, 1996.
41. The Febrile Infant.Presented at Metro Community College Common Pediatric Infections Workshop, Omaha, NE, November 2, 1995
42. RSV. Presented to the Platte-Loup Medical Society.Columbus, NE.January 24, 1995.
43. RSV-related illness and current treatments.Presented at St. Agnes Hospital.Fond du Lac, WI.January 19, 1995.
44. The febrile infant. Presented at Lincoln General Hospital.Lincoln, NE.January 14, 1995.
45. An overview of RSV. Presented at Mary Lanning Memorial Hospital.Hastings, NE.January 6, 1995.
46. RSV bronchiolits. Presented at Good Samaritan Hospital.Kearney, NE.December 16, 1994.
47. Recent Developments in Pediatric Infectious Diseases: 1994. Pediatric Fellowship Program. Children's Hospital, Omaha, NE. December 10, 1994.
48. Resurgence of Tuberculosis.Presented as part of the conference Little Kids: Big Problems.A Pediatric Infectious Disease Symposium.Denver, CO. September 25, 1992.
49. Pediatric HIV and AIDS.Presented at the Pediatric AIDS Update. Greeley, CO. April 7, 1992.
50. Meningitis in the Neurosurgical Patient.Presented to the American Association of Neurosurgical Nurses- Rocky Mountain Chapter.Denver, CO. February 12, 1992.
51. Tick Talk.Presented as part of the conference Little Kids: Big Problems.A Pediatric Infectious Disease SymposiumDenver, CO. June 21, 1991.
52. Neonatal Enterovirus Infection.Presented at Recognition and Care of the Critically Ill Neonate and Child.Presented by The Children's Medical Center at Stony Brook, Children's Hospital of the University Hospital, Department of Pediatrics, School of Medicine.September 16-17, 1987.

Non-CME Invited Presentations:

1. Cultural Competency for Health Providers, Binational Health Week Inauguration, Metropolitan Community College, Omaha, NE, October 9, 2006.
2. Summary of the Findings: Minority Behavioral Health Risk Factor Survey (Douglas and Sarpy County, Nebraska). Urban League of Nebraska Community Forum, Omaha, NE, April 28, 2005.
3. Overview of Economic and Health Indicators Among Omaha’s Latinos. The Second Cumbre of the Great Plains: Re-Visioning Latino America: New Perspectives on Migration, Transnationalism and Integration, Office of Latino/Latin American Studies, University of Nebraska at Omaha, Omaha, NE, April 23, 2005.
4. Addressing Health Care Disparities.Keynote address presented at Minority Graduate Recognition Reception, University of Nebraska Medical Center, Omaha, NE, May 8, 2002.
5. Latinos and the Batalla de Puebla. Cinco de Mayo Lecture, University of Nebraska Medical Center, Omaha, NE, May 4, 2001.
6. Machismo in the New Millennium.Keynote address presented at Seventh Annual Latino Conference, University of Nebraska at Omaha, Omaha, NE, March 22, 1999.
7. A young investigator’s view of research.Presented at Grant Skills Institute Meeting, University of Nebraska Medical Center, Omaha, NE, June 5, 1997.
8. Sexually Transmitted Diseases in Adolescents- HIV Infection.Presented to The Suffolk Coalition for Parents and Children. October 1987.

Research Support: Grants, Clinical Studies, Contracts

Principal Investigator- Active Studies:

1. NIH-NIAID Collaborative Antiviral Study Group - A double blind, placebo-controlled, virologic efficacy trial of pleconaril (VP63843) in the treatment of neonates with enteroviral sepsis syndrome.
   Protocol number: NIH-CASG 106
   Funding source: NIH-NIAID Collaborative Antiviral Study Group
   Funding: $21,021 per subject
   Period of funding:June 1999- July 2010
   Principal Investigator- Completed Studies:
2. Clinical Evaluation of -----------------------------------
   Protocol Number:B0243
   Funding Source:----------
   Funding:--------
   Period of Funding: Febuary 2008 – July 2008
   
3. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate a Single -----------
   -------------------------------------------------------------------------------------------------------------------
   -----------------------------------------------------------------------------------------------
   -------
   Protocol Number:MI-CP-141
   Funding Source:MedImmune, Inc.
   Funding:-------
   Period of Funding: October 2007 – July 2008
4. NIH-NIAID Collaborative Antiviral Study Group - A pharmacokinetic/pharmacodynamicand safety evaluation of Oseltamivir (Tamiflu®) for the treatment of children less than 24 months of age with confirmed influenza infection.
   Protocol Number:CASG114
   Funding Source:NIH-NIAID Collaborative Antiviral Study Group
   Funding:$36,288
   Period of Funding: October 2007 – July 2008
5. Clinical Research Contract – An epidemiological study to evaluate the seasonality of respiratory syncytial virus-associated lower respiratory tract infections (LRI) or apnea in infants in the emergency department.
   Protocol Number:MI-MA133
   Funding Source:MedImmune, Inc.
   Funding: -------
   Period of Funding:October 2006 – May 2008
6. Clinical Research Contract – A prospective, non-interventional study to evaluate the incidence of hospitalizations and medically-attended lower respiratory tract infection (MALRI) in premature infants 32 to 35 weeks gestational age who are not recommended to receive prophylaxis for RSV.
   Protocol Number:MI-MA140
   Funding Source:MedImmune, Inc.
   Funding:-------
   Period of Funding:December 2006 – December 2007
7. NIH-NIAID Collaborative Antiviral Study Group - A Phase II pharmacokinetic and pharmacodynamic evaluation of oral valganciclovir in neonates with symptomatic congenital cytomegalovirus (CMV) infection involving the central nervous system. 
   Protocol Number: 
   Funding Source:NIH-NIAID Collaborative Antiviral Study Group
   Funding: 
   Period of Funding:September 2004-2005
8. Clinical Research Contract - A multicenter, randomized, open-label, comparative study to compare the efficacy and safety of ------------ and standard of care therapy in the treatment of children with ---------------------------- in the hospitalized or outpatient setting.
   Protocol number: LOFBIV-PCAP-003 (PRI/LOF-INT-1)
   Funding Source:Johnson & Johnson Pharmaceutical Research and Development.
   Funding: -------
   Period of funding: April 2002-April 2005
9. Clinical Research Contract - A multicenter, randomized, comparative study to evaluate the efficacy and safety of ------------ in treatment of children who have recurrent and/or persistent acute ------------
   Protocol number:LOFBO-OTMD-002 (PRI/LOF-INT-2); Phase 3
   Funding Source:Johnson & Johnson Pharmaceutical Research and Development.
   Funding:-------.
   Period of Funding:November 2002 – April 2005
10. Clinical Research Contract – Evaluate the safety, tolerability, pharmacodinetics and immunogenicity of -------- in children with hemodynamically ----------------------------disease.
    Protocol number:MI-CP124
    Funding Source:MedImmune, Inc.
    Funding: --------
    Period of Funding:September 2005-October 2006
11. Clinical Research Contract – A pivotal Phase 3 study of -------------------------------------
    ---------------------------------------------------------------------------------------------
    ---------------------------------. 
    Protocol Number:MI-CP110
    Funding Source: MedImmune, Inc.
    Funding: --------
    Period of Funding:September 2004 – August 2006
12. Clinical Research Contract – GlaxoSmithKline (GSK) Biologicals inactivated hepatitis A vaccine (Havrix) containing --- ELISA Units (EL.U.) of hepatitis A antigen per 0.5 mL dose absorbed onto ------- of aluminum hydroxide. 
    Protocol Number: 2-91-022-(HAV-220)
    Funding Source: GlaxoSmithKline (GSK)
    Funding: -------
    Period of Funding:September 2003 – July 2004
13. Clinical Research Contract – A randomized, double blind trial to assess the safety and relative efficacy of ------ against inactivated influenzae vaccine in children 6-59 months of age. 
    Protocol Number:MI-CP111
    Funding Source: MedImmune, Inc.
    Funding: --------
    Period of Funding:September 2004 – December 2005
14. Clinical Research Contract – Clinical evaluation of the ---------------------------- Test
    Funding Source:bioMérieux, Inc.
    Funding:-------
    Period of Funding:June 2005 – September 2005
15. Clinical Research Contract – An open-label, single-arm trial to assess the shedding, immunogenicity and safety of Flu-Mist administered to healthy individuals 5-59 years of age. 
    Protocol Number:FM026
    Funding Source:MedImmune, Inc.
    Funding: -----------
    Period of Funding:June 2004-June 2005
16. Clinical Research Contract - A Phase III, double-blind, randomized, comparative, multicenter study of the immunogenicity and safety of three doses of GlaxoSmithKline Biologicals’thiomersal-free hepatitis B vaccine (10 mcg/0.5 ml) compared to the US-liscenced GlaxoSmithKline Biologicals’ preservative-free hepatitis B vaccine (Engerix-B, 10 mcg/0.5 ml) when administered intramuscularly on a 0, 1, 6-month schedule to healthy infants in their first two weeks of life. 
    Protocol Number:
    Funding Source: GlaxoSmithKline Biologicals 
    Funding:--------
    Period of funding: May 2003 – June 2005
17. Investigator Initiated Research – Latent tuberculosis infection (LTBI): Prevalence and epidemiology in Nebraska and evaluation of three methods of Pediatric LTBI prophylaxis.
    Funding Source:Minority Health, Education and Research Office, UNMC
    Funding:-------
    Period of Funding:March 2005 – October 2006
18. Investigator Initiated Research – Measuring the impact of social marketing on testing for sexually transmitted diseases in a predominantly African American community.
    Funding Source: Minority Health, Education and Research Office, University of NE Medical Center
    Funding:-------
    Period of Funding: March 2005 – July 2006
19. Clinical Research Contract - Pre-booster Concentration of Anti-PRP Antibodies in Serum Samples Obtained from Toddlers (12-18 months of age) who have Completed the Primary Series of Vaccination with Licensed HIB-containing Vaccines.
    Protocol number: EM501 
    Funding Source: Aventis Pasteur
    Funding: ------- 
    Period of funding:May 2003 - February 2004
20. Investigator Initiated Research Contract - Respiratory Viral Testing Survey: A questionnaire-based study of 400 emergency room and clinical laboratory directors.
    Protocol number:N/A 
    Funding Source: MedImmune, Inc. 
    Funding: -------
    Period of Funding:January-May 2004
21. Clinical Research Contract - Synagis® (palivizumab) outcomes registry. 
    Protocol number: None
    Funding Source: MedImmune.
    Funding: None
    Period of funding:October 2003 – May 2004
22. Investigator Initiated Research - A compassionate use study of ---------- in the treatment of severe ------------ illness in adults, children and neonates. 
    Protocol number: VP843-038
    Funding source: ViroPharma, Inc.
    Funding: None 
    Period of funding: August 1997-February 2004
23. Clinical Research Contract - A comparison of safety and efficacy of ------------------------ versus ------------ in Pediatric Subjects with Acute Otitis Media 
    Protocol number:M03-630
    Funding Source:Abbott Laboratories
    Funding:------
    Period of funding:November 2003 – March 2004
24. Clinical Research Contract - A multicenter, long-term, active-surveillance study of musculoskeletal disorders that occur after initiating a course of ----------------------------------- therapy for acute infectious diseases in children who were enrolled in Phase 3 clinical trials involving 
    ----------- therapy.
    Protocol number: LOFBO-LTSS-001
    Funding Source: Johnson & Johnson Pharmaceutical Research and Development
    Funding: -------
    Period of funding: April 2002-November 2003
25. Clinical Research Contract -A Phase IV Comparative Study of the Safety and Efficacy of -------- ---------------, versus ----------------------- in Pediatric Subjects with Otitis Media
    Protocol number:M02-541 
    Funding Source:Abbott Laboratories 
    Funding:----- 
    Period of funding: April - July 2003
26. Clinical Research Contract - A phase III, observer-blinded, randomized, multicenter, clinical study of the safety, immunogenicity and consistency of three manufacturing lots of GlaxoSmithKline Biologicals’ dTaP candidate vaccine as compared to a US-licensed Td vaccine (Massachusetts Public Health Laboratories) when given as a booster dose to healthy adolescents (10-18 yrs of age).
    Protocol number:776423/001 (dTpa 0.3-001)
    Funding Source: GlaxoSmithKline Biologicals’ 
    Funding--------
    Period of funding: October 2002-September 2003
27. Clinical Research Contract - A randomized, placebo-controlled trial to assess safety, tolerability and immunogenicity of influenza virus vaccine, trivalent, types A and B, life cold-adapted (FluMist^TM) and measles, mumps, rubella (MMRIIO) and varicella (VARIVAXO) vaccines administered concurrently to healthy children.
    Protocol number: AV018
    Funding Source: MedImmune 
    Funding: ------- 
    Period of funding:April-December2002
28. Clinical Research Contract - Synagis® (palivizumab) outcomes registry. 
    Protocol number: N/A
    Funding Source: MedImmune 
    Funding: ------
    Period of funding:October 2001-May 2002
29. Clinical Research Contract - A double blind, placebo-controlled, randomized study to evaluate the efficacy and safety of prophylactic administration of ---------- in the prevention of ------------ respiratory illness in healthy adult subjects.
    Protocol number: VP843-062
    Funding Source: ViroPharma, Inc.
    Funding:--------
    Period of funding: September 2001-March 2002
30. Clinical Research Contract - A randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, virologic activity, and safety of ---------- (oral suspension) in the treatment of viral respiratory infection in children 7 to 12 years of age.
    Protocol number: VP843-059
    Funding Source: ViroPharma, Inc.
    Funding:------ per patient
    Period of funding:September 2001-March 2002
31. Clinical Research Contract- A randomized, double blind, placebo-controlled study to evaluate the clinical efficacy, virologic activity, and safety of ---------- (oral suspension) in the treatment of viral respiratory infection in children 1-6 years of age.
    Protocol number: VP843-061
    Funding Source: ViroPharma, Inc. 
    Funding:------ per patient.
    Period of funding:September 2001-March 2002
32. John A. Wiebe, Jr. Children’s Health Care Fund - Molecular characterization of the genomic determinant of cardiovirulence in coxsackievirus B3 clinical isolates. 
    Protocol number: 0002-106 
    Funding source: John A. Wiebe, Jr. Children’s Health Care Fund
    Funding: --------.
    Period of funding: April 2001-October 2003
33. Clinical Research Contract - A natural history study of neonates with enteroviral sepsis syndrome. Protocol number: VP843-041 
    IRB number:
    Funding source: ViroPharma, Inc. 
    Funding: ------------.
    Period of funding: September 2000-2003
34. Edna Ittner Pediatric Research Grant- Molecular epidemiology of coxsackievirus B3: 1954-1998. Protocol number: EI 0300 
    Funding source: Edna Ittner Pediatric Research Foundation
    Funding: ------- 
    Period of funding: July 1999-June 2001
35. NIH-NIAID Collaborative Antiviral Study Group - A double blind, placebo-controlled, virologic efficacy trial of pleconaril (VP63843) in the treatment of infants with enteroviral meningitis. Protocol number: NIH-CASG 107 
    Funding source: NIH-NIAID Collaborative Antiviral Study Group 
    Funding: $2,000 per subject.
    Period of funding: June 1999-2002
36. John A. Wiebe, Jr. Children’s Health Care Fund - Molecular epidemiology of Coxsackievirus B3 in the United States: Genomic and antigenic diversity of clinical isolates from 1956-1998.
    Protocol number: 99-011-09 
    Funding source: John A. Wiebe, Jr. Children’s Health Care Fund
    Funding: -------.
    Period of funding: July 1999-June 2001
37. National Science Foundation NE-EPSCoR Grant - Non-receptor determinants of species and tissue tropism of the picornaviridae. 
    Protocol number: EPS 972-0643 
    Funding source: National Science Foundation NE-EPSCoR Grant
    Funding: -------
    Period of funding: February 1999-January 2001
38. Clinical Research Contract - Natural history study of viral meningitis in young children (4-7 years of age).
    Protocol number: VP843-033 
    Funding source: ViroPharma, Inc.
    Funding: ------ per patient. 
    Period of funding: October 1999-October 2000
39. Clinical Research Contract - An open-label, single and multiple dose pharmacokinetics evaluation of the liquid formulation of ---------- in pediatric patients with acute enteroviral meningitis. 
    Protocol number: VP843-033 
    Funding source: ViroPharma, Inc. 
    Funding: ------ per patient. 
    Period of funding: October 1999-October 2000
40. Clinical Research Contract - A double blind, randomized, placebo controlled evaluation of ---------- in the prevention of otitis media in children with a history of otitis media following -------------- respiratory infection.
    Protocol number: VP843-023
    Funding source: ViroPharma, Inc.
    Funding: ------ per subject
    Period of funding:August 1998 - May 2001
41. Edna Ittner Pediatric Research Grant-Virulence determination in clinical isolates of coxsackievirus B3. 
    Protocol number: EI 843-97-109-08 
    Funding source: Edna Ittner Pediatric Research Foundation
    Funding: ------- 
    Period of funding:July 1997-June 1999
42. Clinical Research Contract - A double blind, placebo controlled trial of VP63843 in the treatment of enteroviral meningitis in adolescents and children. 
    Protocol number: VP843-019 
    Funding source: ViroPharma, Inc.
    Funding: -------
    Period of funding: November 1998 - June 1999
43. Clinical Research Contract - A double blind, placebo controlled trial of VP63843 in the treatment of enteroviral meningitis in adolescents and adults. 
    Protocol number: VP843-018 
    Funding source: ViroPharma, Inc.
    Funding: ------
    Period of funding: November 1998 - June 1999
44. Clinical Research Contract - A double blind, placebo controlled trial of VP63843 in the treatment of enteroviral meningitis in adolescents and children. 
    Protocol number: VP843-012 
    Funding source: ViroPharma, Inc.
    Funding: ------ per subject. 
    Period of funding: May 1997-November 1998
45. Clinical Research Contract - A double blind, placebo controlled trial of VP63843 in the treatment of enteroviral meningitis in adolescents and adults. 
    Protocol number: VP843-009 
    Funding source: ViroPharma, Inc
    Funding: ------ per subject 
    Period of funding: May 1997-November 1998
46. John A. Wiebe, Jr. Children’s Health Care Fund - Outcome based research to assess the impact of reverse transcription polymerase chain reaction diagnosis of enterovirus infections on patient management and health care costs. 
    Funding source: John A. Wiebe, Jr. Children’s Health Care Fund
    Funding: -------
    Period of funding: May 1997-April 1998
47. Primary Care/Outcomes Seed Grant - Effect of rapid diagnosis of enteroviral infections using RT-PCR on patient care and health care costs.
    Funding source: University of Nebraska Medical Center
    Funding: ------.
    Period of funding: July 1996-June 1998
48. Clinical Research Contract - A double blind, placebo controlled phase II study to determine the effect of two dose levels of VP63843 on the natural history of adult aseptic meningitis. 
    Funding source: ViroPharma, Inc.
    Funding: ------ per subject. 
    Period of funding: June 1996-November 1996
49. Health Futures Foundation Grant - Translational initiation among echoviruses with different neurovirulent phenotypes. 
    IRB number: N/A
    Funding source: Health Futures Foundation, Creighton University
    Funding: -------
    Period of funding: November 1995-October 1997
50. Ryan White Title IV HIV Program for Children Research Grant - Number 1MCH-PRW801-01-0.Period of funding: August 1995-July 1998.Collaboration with University of Colorado Health Sciences Center, Denver, CO.
51. Investigator Initiated Research Contract - Evaluation of the potential health care cost savings of rapid enteroviral diagnosis in the management of the febrile infant. 
    Funding source: Roche Molecular Systems
    Funding: --------- (supplies and reagents)
    Period of funding: August 1995-January 1996
52. NIH Research Supplement for Underrepresented Minority Investigators - Supplement to grant 2R01 HL 4030-482-NHLBI/NIH 
    Funding source: NHLBI/NIH 
    Funding: $84,864 total direct cost.
    Period of funding: March 1995-February 1996
53. Seed Research Grant - University of Nebraska Medical Center; Funding: ----------- Period of funding: July 1994 - June 1995.Declined by recipient.
54. NIH Research Supplement for Underrepresented Minority Investigators - Supplement to grant number 2RO1 HL 40303-05- 
    Funding source: NHLBI/NIH 
    Funding:$59,382
    Period of funding: March 1994-January 1995
55. Edna Ittner Pediatric Research Support Grant - Sequencing, cloning and functional analysis of the 5’NTR of phenotypically distinct echoviruses 
    Funding source: Edna Ittner Foundation
    Funding: -------
    Period of funding: July 1994 - September 1995
56. Minority Medical Faculty Development Grant - Sequencing of echovirus 9 (Hill strain) and Role of the 5’NTR in echovirus pathogenesis. 
    Funding source: Robert Wood Johnson Foundation 
    Funding: --------
    Period of funding: July 1991-June 1993
57. Minority Medical Faculty Development Grant - Polyclonal antibodies to the poliovirus VP3 and 2C proteins for the detection of the human enteroviruses and Cloning of echovirus 9 (Hill strain).
    Funding source: Robert Wood Johnson Foundation 
    Funding: -------- 
    Period of funding: July 1987-June 1989

Co-Investigator:

1. A multi-center study of the efficacy, safety, tolerability and immunogenicity of the heptavalent formulation of a pneumococcal conjugate vaccine containing serotypes ---------------------------------- ------- for protection against acute otitis media due to pneumococcal serotypes n the vaccine. Merck. Period of funding: January 1993-1996.Funding: ------ per subject. Principal Investigator: Stephen A. Chartrand, M.D.Co-Investigators:Christopher J. Harrison, M.D. and José R. Romero, M.D.
2. Evaluation of erythromycin in the treatment of pneumonia in children: A randomized, double blind trial employing amoxicillin/clavulanate or erythromycin estolate as comparative standard therapy. Pfizer.January 1994-1995. Funding: ------ per subject. Principal Investigator: Christopher J. Harrison, M.D .Co-Investigators: Stephen A. Chartrand, M.D. and José R. Romero, M.D.
3. A single blind comparative trial of the safety and immunogenicity of a tablet formulation of the ----------------------------------------------------------------- versus the lyophilized formulation of the --------------------------------------------------------------. Wyeth.Period of funding: February 1994-1995.Funding: ---- per subject. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
4. A Phase II randomized, double blind, placebo-controlled trial of ----------------------------------------- infusions of reduction of the rate of RSV hospitalizations in premature infants and infants with bronchopulmonary dysplasia (MI-RSV-9401).MedImmune.Period of funding: December 1994-June 1995. Funding: ------ per subject.Principal Investigator:Stephen A. Chartrand, M.D.Co-Investigators:José R. Romero, M.D., Christopher J. Harrison, M.D. and Daniel J. Boken, M.D.
5. A Phase I randomized multicenter study to determine the optimal dose and immunization schedule of BIOCINE CMV gB vaccine in CMV-seronegative adults.Biocine.Period of funding: January 1995-May 1996.Funding: ------ per subject.Principal Investigator: Christopher J. Harrison, M.D.Co-Investigators:Stephen A. Chartrand, M.D., José R. Romero, M.D., Daniel J. Boken, M.D.
6. A phase II, double blind, randomized, multicenter study of Biocine® CMV gB vaccine in CMV-seronegative adults.Biocine.Period of funding: July 1995-August 1997.Funding: ------ per subject.Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., Daniel J. Boken, M.D., Alice Pong, M.D., and Archana Chatterjee, M.D.
7. A double-blind, randomized, placebo-controlled study to assess the safety and efficacy of multiple IM doses of SB209763 in infants and young children with underlying disease as prophylaxis against the development of serious Respiratory Syncytial Virus (RSV) infection.SmithKline Beecham.Period of funding: August 1995-June 1996.Funding: ------ per subject.Principal Investigator:Stephen A. Chartrand, M.D.Co-Investigators:Mark C. Wilson, M.D., Christopher J. Harrison, M.D., and José R. Romero, M.D.
8. A Phase III, double-blind, randomized, parallel design, multicenter, lot-to-lot consistency study of the safety, tolerability and immunogenicity of an HSV vaccine composed of ---------------------------- ----------------------------------- subunit antigens combined with -------------------------------------- when given to healthy HSV-2 seronegative adults.Biocine.Period of funding:October 1995-November 1996. Funding: --------- per subject.Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., Daniel J. Boken, M.D.
9. Safety and immunogenicity in healthy infants of diphtheria and tetanus toxoids and five-component acellular pertussis vaccine.Connaught.Period of funding:December 1995-1996. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
10. Comparison of -------------------- oral suspension --------- vs. -------- oral suspension --------- in the treatment of acute suppurative otitis media in infants and children.Upjohn.Period of Funding: February-June 1996.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
11. Multicenter study of the safety, tolerability and immunogenicity of concomitant injections in separate sites of COMVAX, MMR, and VARIVAX in healthy children vs. injection of COMVAX followed six weeks later by MMR and VARIVAX. Merck.Period of Funding: June 1996-June 1997.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
12. A double-blind placebo-controlled study to evaluate the safety and immunogenicity of a fourth dose of the Tetravalent Rotavirus Vaccine (RV-TV) in children 14 to 24 months of age. Wyeth. Period of Funding: August-September 1996. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
13. A phase II multicenter, observer-blind, controlled randomized study to compare the safety and immunogenicity of ----- ---- -------- ------ to ------ ------- administered to healthy children 5 months to 17 years of age. Chiron Biocine.Period of funding: September 1996-June 1997. Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators:Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
14. A double-blind, randomized, placebo-controlled study to evaluate the safety of SmithKline Beecham Biologicals’’ ------------------------------------------------ in HSV seropositive or seronegative subjects without genital disease.SmithKline Beecham.Period of funding:October 1996-June 1998.Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
15. A double-blind, randomized, placebo-controlled study to evaluate the safety of SmithKline Beecham Biologicals’’ ---------- ---- ------ --- ---- --- ----- --- ----- --- ------ ------ -- and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease. SmithKline Beecham.Period of funding:October 1996-June 1998. Investigator: Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
16. A phase I, observer-blind, placebo-controlled study of the Chiron ------- --- - ------- - vaccine administered to healthy HIV-seronegative adults.Chiron Biocine.Period of funding:December 1996-December 1998.Principal Investigator: Christopher J. Harrison, M.D. Co-Investigator: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
17. Lorabid in acute otitis media: ----------------. Lilly. Period of funding: January 1997-February 1998. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
18. A comparison of the safety and efficacy of every 12 hours Augmentin, ----------------, and every 12 hours Augmentin, ----------------, in the treatment of acute otitis media in children.
19. SmithKline Beecham.Period of funding: January-March 1997.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
20. A single blind, randomized, multi-center study to assess the safety and efficacy of 5 days of Augmentin® every -- hours (----------------) compared with Zithromax® every -- hours (-- --------------------------------------) in the treatment of acute otitis media in infants and children. SmithKline Beecham.Period of funding:January-June 1997.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
21. A large-scale safety study of a combination Haemophilus b conjugate vaccine (meningococcal protein conjugate), recombinant hepatitis B vaccine and poliovirus vaccine inactivated, combined (PRI) in healthy infants.Connaught.Period of funding: July 1997-August 1998.Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
22. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human-bovine rotavirus in a new buffer/stabilizer liquid formulation.Merck.Period of funding:September 1997-June 1998. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
23. Health economic study of outpatient meropenem for injection among children recovering from complicated appendicitis.Zeneca.Period of funding: November 1997-January 1999. Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
24. A single-blind, randomized, multicenter study to assess the bacteriological outcome of Augmentin ---------------vs. Zithromax® -------- days in the treatment of acute otitis media in infants and children. SmithKline Beecham.Period of funding: December 1997-March 1998. Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
25. A phase II, multicenter, observer-blind, controlled, randomized study in healthy toddler to compare the study and immunogenicity of Chiron meningococcal C conjugate vaccine reconstituted with 1 of 2 lots of aluminum hydroxide adjuvant.Chiron. Period of funding: December 1997-March 1999.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
26. Efficacy and initial pharmacokinetics of high dose and standard dose penicillin V in the treatment of group A streptococcal pharyngitis and/or tonsillitis.Creighton University.Period of funding: March 1998-March 1999. Principal Investigator: Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
27. Comparison of the safety, tolerability and immunogenicity of ------- process upgrade varicella vaccine administered concomitantly with M-M-R.Merck.Period of funding: March-October 1998.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
28. A phase III, open-label, multicenter study to evaluate the safety, tolerability and immunogenicity of Chiron meningococcal C conjugate vaccine in healthy toddlers. Chiron.Period of funding: August-December 1998.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
29. Linezolid in the treatment of community-acquired pneumonia in patients aged 12 months to 6 years. Upjohn. Period of funding: August 1998-April 1999.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
30. A randomized, comparative study of alatrofloxacin vs. ceftriaxone with optional ---------- in children with bacterial meningitis.Pfizer. Period of funding: August 1998-Present. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
31. A Phase III open randomized controlled study of the safety and immunogenicity of three doses of SmithKline Beecham Biologicals’ Dta-HBV-IPV/Hib vaccine administered at 2, 4, and 6 months of age following a birth dose of Engerix-B compared to three doses of SmithKline Beecham Biologicals’’ DtPa-HBV-IPV/Hib vaccine administered at 2, 4 and 6 months of age without a birth dose of hepatitis B vaccine.SmithKline Beecham.Period of funding: December 1998-December 1999.Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
32. Study of pilot manufacturing of HPV virus-like particle (VLP) infection in 16 to 23-year-old females. Merck. Period of funding:December 1998-Present.Principal Investigator:Christopher J. Harrison, M.D.Co-Investigators: Stephen A. Chartrand, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
33. A multicenter randomized double-blind safety and tolerability study with in-house blinding procedures comparing --------------------------------- varicella vaccine with VARIVAX® in healthy children. Merck. Period of funding:February-July 1999.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
34. An open-label study to demonstrate bacteriologic efficacy of Augmentin ES in the treatment of AOM due to S. pneumoniae with amoxicillin ---------------. SmithKline Beecham. Period of funding: March 1999-March 2000. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
35. An open, randomized, multicenter study of the safety, tolerability and immunogenicity of VAQTA™ given concomitantly vs. non-concomitantly with other pediatric vaccines in children approximately 12 months of age. Merck. Period of funding: April 1999-April 2001.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
36. Comparison of the safety, tolerability and immunogenicity of --------------- varicella vaccine made with -------------- to process upgrade varicella vaccine made with ------------------ when administered concomitantly with MMR™II. Merck.Period of funding:October 1999-April 2000. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
37. Comparative safety and efficacy of ------------------ and ------------------- suspensions in the treatment of children with acute otitis media.TAP Holdings Inc. Funding period: December 1999-December 2000. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
38. A prospective observational study to characterize some disease patterns in patients with recurrent acute bacterial sinusitis.SmithKline Beecham.Funding period:February 2000-March 2001. Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
39. An open-label, multicenter, non-comparative study of ------------ in the treatment of recurrent otitis media in children. Bristol Meyer Squibb. Funding period: February-December 2000.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
40. Safety, immunogenicity and lot-consistency study of Connaught hybrid pertussis vaccine in combination with diphtheria and tetanus toxoids absorbed and inactivated poliomyelitis vaccine grown on ----------- used to reconstitute lyophilized Haemophilus influenzae Type b tetanus toxoid conjugate vaccine CP_20/20/5/3DT-mlPV/PRP-T) in infants and toddlers.Connaught.Funding period:March 2000-Marach 2002.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
41. --------- vs. ---------- in the treatment of skin and skin structure infections in children. Pharmacia and Upjohn.Funding period:June-December 2000.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: Christopher J. Harrison, M.D., José R. Romero, M.D., and Daniel J. Boken, M.D.
42. Study of pilot manufacturing lot of HPV 16 ------------------------- vaccine in the prevention of HPV 16 infection in 16- to 23-year-old females. [Protocol 005-00]Merck & Co., Inc. Funding period: June 2000-present. Principal Investigator: Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
43. A double-blind, randomized, placebo-controlled study to evaluate the safety of SKB Biologicals’’ herpes simplex candidate vaccine --------------- and its efficacy to prevent genital herpes disease in HSV positive or negative consorts of subjects with genital herpes disease.[Protocol208141/037]SmithKlineBeecham Biologicals’.Funding period:July 2000-August 2001. Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
44. Penetration of ---------- into middle ear fluid in infants and children with acute otitis media following a single oral dose of ------------------.TAP Holdings, Inc. Funding period: August 2000-February 2001.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: José R. Romero, M.D., and Archana Chatterjee, M.D.
45. A prospective, open-label, non-randomized, naturalistic, long-term safety surveillance, observational study of ciprofloxacin (either as oral suspension, oral tablets or sequential IV Ýoral therapy or purely IV therapy) in the treatment of pediatric patients with a variety of infectious diseases. [Protocol 100-21]Bayer.Funding period:September 2000-present.Principal Investigator: Stephen A. Chartrand, M.D.Co-investigators: José R. Romero, M.D., and Archana Chatterjee, M.D.
46. Safety and efficacy of pentavalent human-bovine rotavirus vaccine in healthy infants.[Protocol V260/006]Merck.Funding period: September 2000-present.Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
47. A randomized, investigator-blinded, multicenter, comparative study of ------------ vs. --------- --------------------------------- in the treatment of recurrent otitis media and acute otitis media treatment failures in children.[Protocol AI420-078]Bristol-Meyer Squibb.Funding period: November 2000-November 2003.Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
48. An open, randomized, multicenter study of the safety, tolerability and immunogenicity of frozen ---- given concomitantly vs. non-concomitantly with other pediatric vaccine in healthy children 12-15 months of age.[Protocol 013-02] Merck. Funding period: February 2001-February 2004. Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
49. ------------------ vs --------------- for the treatment of resistant gram-positive bacterial infections in children.[Protocol M/1260/0082]Pharmacia & Upjohn.Funding period: March 2001-April 2002. Principal Investigator: Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
50. A comparative trial of the safety of one dose of an -------------------------------------------- --------------------------------------------------------- in healthy children in the U.S. aged 11-18 years. [Protocol MT A04] Aventis. Funding period: May 2001-April 2003. Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.
51. A prospective, multicenter, double blind, randomized, comparative study to evaluate the safety, local tolerability and clinical outcome of -------------------------- vs. ------------------ in pediatric patients with complicated urinary tract infection, skin and soft tissue infection, or community-acquired pneumonia. [Protocol 036-00] Merck. Funding period: May 2001-April 2004. Principal Investigator: Archana Chatterjee, M.D.Co-investigator: José R. Romero, M.D.
52. Open study to further evaluate the safety and reactogenicity of GSK Biologicals’’ prophylactic herpes simplex candidate vaccine with ----------- in HSV-1 and HSV-2 seronegative (HSV 1-/2-) women who previously received either ---------------- as placebo during one of GSK Biologicals’’ Phase III studies 10813/005, 208141 or 108141/017. [Protocol 108141/037] GlaxoSmithKline. Funding period: February 2002-March 2003. Principal Investigator:Archana Chatterjee, M.D.Co-investigator:José R. Romero, M.D.